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Abstract 
Huntington‟s disease (HD) is a fatal, neurodegenerative movement disorder caused by a 
CAG repeat expansion on the gene encoding the huntinin protein.  HD is characterized by 
preferential and extensive striatal degeneration.  We used fast-scan cyclic voltammetry to 
measure dopamine release and reserve pool dopamine in genetically and chemically altered 
rodents that model HD.  Genetic HD model mice and rats (R6/1 mice, R/2 mice, and HDtg rats) 
showed an age-dependent decrease in dopamine release in the dorsolateral caudate putamen.  A 
similar decrease is not seen in 3-nitropropionic (3NP)-treated rats.  In the case of R6/2 mice, 
stimulation at increasing frequencies showed a decrease in dopamine at the highest frequencies 
of 50 Hz and 60 Hz.  The number of reserve pool vesicles was found to decrease in the R6/2 
mice while it increased in the 3NP treated rats.   
In a separate study, methionine sulfoxide reductase A (MsrA) mice, which model 
oxidative stress, have been reported to have chronically high dopamine levels relative to control 
mice. Additionally, these high levels parallel an increased presynaptic dopamine release when 
stimulated in vitro without drug treatments. Here we show evidence in striatal tissue for an 
increase in dopaminergic reserve pools that correlates to the increased dopamine levels of this 
knockout mouse. The results suggest that dopamine in reserve pool vesicles accumulates in the 
MrsA knockout mouse.   This evidence supports previous reports that suggest the amount of 
dopamine in reserve pools is dependent on the overall dopamine levels, including readily 
releasable dopamine vesicles.   
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Chapter 1: Introduction 
Using electrochemical methods allows for the detection of electro-active chemicals.  In our 
studies we are most interested in measuring dopamine in brain slices of rats and mice.  Using 
cyclic voltammetry we have a method that allows for good spatial and temporal resolution and 
will cause very little harm to brain tissue allowing us measure dopamine in vivo. 
A. Fast Scan Cyclic Voltammetry 
Fast-scan cyclic voltammetry (FSCV) at carbon-fiber microelectrodes is an analytical 
technique that has often been used to measure electro-active neurochemicals, such as dopamine, 
serotonin, norepinephrine, and epinephrine (Wightman et al., 1988, Wightman et al., 1991, 
Robinson et al., 2003, John et al., 2006).  The use of FSCV provides several advantages, 
including: low (nM) limits of detection, excellent (sub-s to near ms) temporal resolution, good 
(µm) spatial resolution, and reasonable chemical selectivity for the analyte of interest (a 
characteristic cyclic voltammogram is generated) (Robinson et al., 2003).  Moreover, 
measurements using carbon-fiber microelectrodes are particularly well-suited for obtaining 
chemical measurements in biological tissues, neuronal tissues in particular, because damage to 
the tissue is minimized.    
When conducting measurements using FSCV in neuronal tissue a triangular waveform if 
often applied in which a holding potential of -0.4 V (versus Ag/AgCl reference electrode) is 
applied to the carbon-fiber microelectrode.  The potential is then linearly increased to +1.0 V and 
then decreased back down to -0.4 V.  A scan rate often used in conjunction with this waveform, 
at least when measuring dopamine, is 300 V/s.  The waveform application frequency is typically 
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10 scans/s, allowing for the collection of 10 cyclic voltammograms (CVs) per second.  When 
using this waveform, the oxidation and reduction of DA is a two electron process. 
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Figure 1. The oxidation and reduction of DA is a two electron process as shown in 1A.  Using 
FSCV the current is plotted against applied voltage as shown in 1B.  The solid line represents the 
background current and the dotted line represents the current that is present in the presence of 
DA.  By subtracting out the background a characteristic CV of DA is given as shown as in 1C. 
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DA is oxidized at about +0.6 V, forming the DA ortho-quinone.  Scanning back down to 
-0.4 V, the DA ortho-quinone is reduced to DA at about -0.2 V.  These oxidation and reduction 
peaks are plotted versus applied potential to give a CV (see Figure 1).  Due to the high scan rate, 
however, a large charging current, which may be several orders of magnitude larger than the 
faradaic current, is formed.  To remove this charging current, a background CV, obtained when 
dopamine is not present, is subtracted from the CV collected in the presence of DA.  This 
background subtraction operation gives a characteristic CV that serves as a “signature” for DA.  
This background subtraction operation is summarized in Figure 1.   
 The concentration of DA is calculated using the average of a pre and post calibration of 
the electrode.  The concentration of DA is proportional the the current calculated for each 
electrode. 
B. Dopamine System 
Dopamine is a catecholamine neurotransmitter associated with many aspects of brain 
function, including behavior, cognition, addiction, and movement, to name just a few (Cooper et 
al., 2003). Therefore, it is not surprising that alterations the regulation of extracellular DA levels 
are associated with a variety of  neurological disorders, including Huntington‟s Disease (HD), 
Parkinson‟s disease (PD), and Tourette‟s syndrome (Barbeau and Ando, 1975, Hornykiewicz, 
2008, Steeves et al., 2010).  Careful study of the DA system, using selected analytical 
techniques, such as FSCV, may allow for a better understanding of how brain function is 
impacted in selected areas of the diseased brain.  In this sub-section, aspects of mammalian CNS 
anatomy that are relevant to these studies are summarized.  Additionally, the dopamine release 
process is reviewed.  Finally, animal models used to study Huntington‟s disease and oxidative 
stress are described.         
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1. Anatomy 
Dopaminergic neurons originate in the substantia nigra pars compacta, ventral tegmental 
areas (VTA), and hypothalmas forming four major dopaminergic pathways.  The four main 
pathways responsible for domainergic intervention to specific areas of the brain; these pathways 
are mesocortical, mesolimbic, tuberoinfundibular, and nigrostriatal pathways.  The mesocortical 
and mesolimbic pathways are used in order to transfer DA from the VTA to the nucleus 
accumbens and the frontal cortex, respectively.  The tuberoinfundibular pathway is involved in 
the transportation of DA from the hypothalamus to the pituitary gland.  The nigrostriatal pathway 
which is involved in the control of motor function transports DA from the substantia nigra to the 
striatum.    
The striatum is the largest integrative part of the basil ganglia, it is here that 
gluatamatergic and dopaminergic inputs converge.   The striatum is located on the interior of the 
forebrain and consists of about 96% medium spiny neurons.  The other types of neurons also 
present in the striatum include Deiters‟ neurons, cholinergic interneurons, GABAergic 
parvalbumin, GABAergic calretinin, and GABAergic somatosstatin.  Medium spiny neurons 
play a key role in controlling motor function by either activating D1 receptors or by inhibiting 
the activation of D2 receptors (DeLong et al., 1984, Alexander et al., 1990).  There are two types 
of medium spiny neurons found in the striatum; one expressing D1 receptors and one expressing 
D2 receptors.  The medium spiny neurons which contain D2 receptors provide an indirect 
pathway to control motor function while the medium spiny neurons containing D1 receptors 
allow for a direct pathway (DeLong et al., 1984, Alexander et al., 1990, Tang et al., 2005, Tang 
et al., 2007, Charvin et al., 2008).   
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The substantia nigra pars compacta (SnC) plays a major role in motor function.  The 
substantia nigra itself cannot control motor function but it is (Yin et al., 2009, Yin, 2010) in 
charge of supplying DA to the striatum leading to fine tuning of motor control.  Dopaminergic 
neurons project from the SnC to the dorsal caudate putamen.  Various behaviors are then 
generated based on the subarea of the striatum that is activated.  The dorsal lateral, dorsal medial, 
and ventral striatum are all associated with learning and behaviors associated with rewards.  The 
dorsal lateral striatum is more specifically associated with behaviors that are learned by a 
stimulus or out of habit while the dorsal medial striatum is associated with behaviors that are a 
response to reward (Wickens et al., 2007, Horvitz, 2009, Yin et al., 2009, Ashby et al., 2010, 
Yin, 2010).  Lesions caused in this area of the brain are present in Parkinson‟s disease and that is 
why it is thought that the there is a loss of motor control in patients with Parkinson‟s disease. 
2. Dopamine 
Dopamine is synthesized in the presynaptic terminals and in the soma starting with the 
hydroxylation of L-tyrosine to L-Dihydroxyphenylamine (L-DOPA).  This is the rate limiting 
step for DA synthesis and is controlled by tyrosine hydroxylase.  L-DOPA is then converted to 
DA via DOPA decarboxylase.  Once DA is synthesized in can then be packaged into vesicles 
through the vesicular monoamine transporter (VMAT).  Vesicles can then stored for later use of 
be released into the synapse where DA can react with autoreceptors or be taken back into the 
presynaptic terminal by the DA transporter (DAT).     
One mode of the release of DA is through exocytosis, which occurs when the vesicle 
membrane fuses with the neuronal membrane.  Exocytosis is a calcium-dependent process.  
When the membrane is depolarized, the voltage-gated calcium channels open, allowing 
extracellular Ca
2+
 to enter.  These Ca
2+ 
ions associate with the SNARE protein complex, which 
13 
 
then causes the vesicle membrane to fuse with the neuronal membrane, and allows the vesicle 
contents to exit into the extracellular space (Becherer and Rettig, 2006).  It is currently thought 
that exocytosis happens in one of two ways:  either classical exocytosis (just described) or in a 
“kiss and run” type action.  In the kiss and run method a fusion pore transiently opens up 
allowing for the release of neurotransmitters.  In the kiss and run method endocytosis of the 
vesicles can happen as fast as a sub-second  (Rizzoli and Betz, 2005).   
After DA is released into the synaptic cleft through exocytosis,  it may either interacts 
with the D1 or D2 autoreceptors, diffuse out the synaptic cleft, or may be taken back up into the 
presynapitc terminal.  In order to be taken back up into the synaptic cleft it has to be transported 
through the DA transporter (DAT) (Garris and Wightman, 1994).  The DAT is an 80 kDA 
protein found on the plasma membrane and contains 12 transmembrane regions as shown in table 
1 (Schenk et al., 2005).  It is a sodium and calcium dependent transporter with the first five 
transmembrane regions being involved in the ion dependence transport.  The transmembrane 
regions six through eight are thought to be target sites for DAT inhibitors such as AMPH and 
COC (Kitayama et al., 1992).  The regions nine through twelve are used to determine substrate 
affinity and stereoselectivity (Giros and Caron, 1993, Buck and Amara, 1994, Buck et al., 1996).  
The DAT is important in dopaminergic signaling and alterations can lead to signaling problems 
affecting downstream pathways. 
 
 
 
 
14 
 
 
 
Transmembrane Region of DAT Function 
1 through 5 Ion dependent transport 
6 through 8 Target site for DAT inhibitors 
9 through 12 Determines substrate affinity and 
stereoselectivity 
 
Table 1.  The DAT is made up of 12 transmembrane regions.  The 12 regions are broken down 
into 3 subgroups that each play an important role.  Regions 1-5 are important for ion dependent 
transport.  Regions 6-8 are target sites for DAT inhibitors such as AMPH, COC, and METH.  
Regions 9-12 are important in determining the affinity and stereoselectivity of various substrates. 
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Synaptic vesicles in the presynaptic terminal are thought to reside in distinct pools. 
Catecholamines are commonly classified into three distinct vesicle pools (as shown in Figure 3), 
although some studies support a four pool system  (Rizzoli and Betz, 2005).  The readily 
releasable pool (RRP) which consists of 0.1%-2% of the total vesicles.  The recycling pool, 
which is used to replenish the RRP vesicles, consists of 5%-20% of all vesicles found in the 
presynaptic terminal.  The third and largest vesicle pool (80%-95% of the vesicles) is the reserve 
pool (Neves and Lagnado, 1999, Zucker and Regehr, 2002, Rizzoli and Betz, 2005). 
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Figure 3.  The three pool system consists of the readily releasable pool, recycling pool, and 
reserve pool.  Readily Releasable Pool makes up ~1% of total vesicle pool and is available upon 
stimulation. The Recycling Pool makes up ~10-15% of the total vesicle pool and is released upon 
moderate stimulation.  The Reserve Pool makes up ~80-90% of total vesicles and is released 
after intense stimulation and is thought to be mobilized after the depletion of Recycling Pool 
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The RRP are a group of vesicles that are primed and docked at the active zone in the 
presynaptic terminal.  They are the easiest and quickest vesicles to mobilize.  The mobilization 
of the RRP is activated upon mild stimulation where the axon terminal is depolarized by an 
action potential (Wu and Borst, 1999).  The stimulation needed in order for the release of the 
RRP can come in the form of electrical stimulation, depolarization lasting a few milliseconds, 
and hypertonic shock (Elmqvist and Quastel, 1965, Rosenmund and Stevens, 1996, 
Schneggenburger et al., 1999, Delgado et al., 2000, Richards et al., 2003).  The RRP is rapidly 
replenished (~1 sec) by vesicles in the recycling pool (Wu and Borst, 1999, Sakaba and Neher, 
2001). 
The recycling pool is the second largest pool accounting for 5-20% of all vesicles in the 
terminal (Richards et al., 2003, Rizzoli and Betz, 2005).  The recycling pool is an intermediate 
stage between the RRP and the reserve pool vesicles.  The recycling pool vesicles are mobilized 
under moderate stimulation and are thought to only mobilize once the RRP vesicles are 
diminished.  The recycling pool vesicles can rapidly be docked and released if needed (a few 
seconds) (Rizzoli and Betz, 2005).  The recycling pool is replenished with vesicles from the 
reserve pool.   
The largest pool of vesicles making up 80-90% of all vesicles is the reserve pool (Rizzoli 
and Betz, 2005).  This pool of vesicles is only released upon intense stimulation and is thought to 
only mobilize once the recycling pool vesicles have diminished.  Using a stimulation frequency 
of 50 Hz with train pulses of 2 and 4 seconds an increase in DA release is found due to the 
mobilization of the reserve pool vesicles (Yavich, 1996, Yavich and MacDonald, 2000).  The 
reserve pool vesicles can also be mobilized through pharmacological means; cocaine has been 
shown to mobilize the synapsin dependent reserve pool vesicles (Venton et al., 2006).      
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C. Huntington’s Disease 
HD  is an autosomal dominant neurodegenerative disorder caused by an expanded CAG 
repeat which codes for a polyglutamine  stretch on the huntingtin gene (htt) (The Huntington's 
Disease Collaborative Research Group, 1993).    The mutated gene is located on chromosome 4 
(The Huntington's Disease Collaborative Research Group, 1993).  The expanded CAG repeat 
causes degeneration of the medium spiny neurons resulting in mood disturbances, choreic 
movement, and cognitive dysfunction(Bates et al., 2002). 
On average the age of onset varies between 35-50 years of age.  The variation in age of 
onset is in part due to the number of CAG repeats a person has.  There is a correlation between 
the number of CAG repeats a person has and the age of onset; where a larger number of CAG 
repeats results in an earlier onset.  Individuals who have less than 28 CAG repeats will not 
develop physical or psychological deficits associated with HD, individuals with ≥40 CAG 
repeats will typically develop the HD syndrome some time during a normal life time.  
Individuals with more than  60 CAG repeats may develop HD symptoms as juveniles (The 
Huntington's Disease Collaborative Research Group, 1993). 
1. Disease Progression 
 As HD progresses it causes movement, cognitive, and psychiatric dysfunction.  
Psychiatric dysfunction, most commonly in the form of depression, usually occur before the 
onset of other more noticeable characteristics such as choriec involuntary movement, impaired 
coordination, dementia, and personality changes (The Huntington's Disease Collaborative 
Research Group, 1993).  The age of onset varies from 35-50 years old, depending on the length 
of the CAG repeat with a typical duration of 15-20 years. 
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One of the main characteristics of HD is the neurodegeneration of the medium spiny 
neurons.  GABAergic neurons make up 85-90% of the striatal neurons and are the main target 
for destruction by HD (Vonsattel et al., 1985, Ross et al., 1997, Vonsattel and DiFiglia, 1998).  
Though the striatal cells are targeted for apoptosis, the reason by which cell death is induced is 
uncertain.  One possible explanation is that mitochondrial dysfunction leads to apoptosis.  It has 
previously been shown in lymphoblasts from HD patients and in various genetic models of HD 
that a reduction in mitochondrial membrane potential is present (Sawa et al., 1999, Panov et al., 
2002, Bae et al., 2005).  HD patients also have been found to have a decrease in the activity of 
mitochondrial complex II (mCII) due to the reduced expression of mCII subunits (Benchoua et 
al., 2006, Benchoua et al., 2008).  The mCII plays a role in oxidative energy metabolism and its 
down regulation has been shown to cause an increase in the vulnerability of striatal neurons to 
the mutant htt toxicity (Benchoua et al., 2008). 
Another possible explanation for the cell death of the medium spiny neurons could be due 
to the formation of reactive oxidative species (ROS).  The main source for ROS is mitochondrial 
dysfunction and impairments in the electron chain. Lipid peroxides are a proposed biomarker to 
measure oxidative stress in vivo for neurological diseases.  When measured blood plasma of HD 
patients, plasma lipid peroxide and lactate concentrations were shown to be elevated, indicating 
the patient was under oxidative stress (Duran et al., , Sayre et al., 2008).  The plasma activity of 
aminopeptidases for aspartate and glutamate were also measured in blood plasma for HD 
patients and it was found to decrease, in both symptomatic and nonsymptomatic patients, 
indicating that there is a decrease in plasma activity before the symptoms of HD can be seen in 
patients (Duran et al.).  Signs of oxidative stress have also been shown to be present in post 
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mortem brains of HD brains including: cytoplasmic lipoofuscin, DNA strand breaks, and 
oxidative markers in DNA bases (Tellez-Nagel et al., 1974, Browne et al., 1999). 
It has also been shown that caspase-1, an enzyme in controlling cellular death is activated 
in both patients and mouse models of HD.  Caspase-1 is activated early on in HD progression 
and it is the earliest caspase activated in HD rodent models (Zhang et al., 2003, Wang et al., 
2005).  The levels of Caspase-1 increase along with disease progression possibly explaining the 
increase in cellular death that also occurs (Chen et al., 2000, Zhang et al., 2003).  
Neurological and behavioral disturbances of HD can be attributed to the selective pattern 
of cell loss in the brain and the pathways that are affected.  Studies using R6/2 mice have shown 
behavior deterioration that resembles that found in HD patients (Carter et al., 1999).  Using 
FSCV our group has previously shown that there is an age dependent DA inhibition in both R6/2 
and R6/1 mice and the reserve pool DA in R6/2 mice is diminished (Johnson et al., 2006, 
Johnson et al., 2007, Ortiz et al., 2010, 2011a). The behavioral impairments found in HD could 
possibly be partially explained by an impairment in the DA release that has been shown in R6/1 
and R6/2 mice models of HD.    
2. Rodents That Model Huntington’s Disease 
In order to study the dynamics of HD, the use of an animal model, in which the disease 
progression is quicker, is often entailed.  The most common rodent models are transgenic mouse 
models.  Until the recent generation of the HD transgenic rat model, rats were treated with 
neurotoxins to create a chemically induced HD rat model. 
a. Mice 
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Various mouse models are available for the study of HD.  There are two main types of 
mouse models, those that have a full length mutant htt gene and those that use a truncated 
version of the gene.  The full length HD model is a yeast artificial chromosome (YAC) 
transgenic mouse model.  The truncated version is the more common mouse models used and are 
generated using the R6 mouse germ line.   
The YAC mouse model uses a full-length human gene that codes for the htt protein.  The 
two mouse models contain CAG repeats similar to that of found in humans with adult onset and 
juvenile onset.  YAC46 contains 46 CAG repeats and represents the adult onset model and the 
YAC72 contains 72 CAG repeats and represents the juvenile onset.   Both the YAC46 and YAC72 
models show early electrophysiological abnormalities.  The YAC46 model though it shows signs 
of electrophysiogical abnormalities at 12 months of age, behavior abnormalities are not present 
until about 20 months.  Behavioral abnormalities are seen in the YAC72 that correlate to the 
amount of htt protein present, mice with higher levels of protein present show an early 
behavioral onset, aggregates, and neruodegeneration of the striatum at about six weeks of age   
The YAC72 model with lower levels htt protein present show electrophysiological abnormalities 
at 4 to 6 months with signs of neurodegeneration at 12 months of age. 
A second type of mouse model that is used to study HD uses a truncated version of the 
human HD gene.  In these models exon 1 of the human HD gene is introduced into the mouse 
germ line using a 2kb fragment that spans the 5‟ end of the human gene (Mangiarini et al., 1996, 
Sathasivam et al., 1999).  To date there are six lines that have been established all with varying 
lengths of CAG repeats.  Four of the models have CAG repeats that are representative of those of 
juvenile HD; R6/1 has 113 CAG repeats, R6/2 with 144 CAG repeats, R6/5 has 128-156 CAG 
repeats, and R6/0 has 142 CAG repeats (Bates et al., 1998, Sathasivam et al., 1999).  The 
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remaining two models HDex6 and HDex27 both are controls with 18 CAG repeats.  Of the six 
HD models from the R6 germ line the R6/1 and R6/2 are the most extensively studied.  Both the 
R6/1 and R6/2 mice show signs of abnormal behavior such as irregular gait, shudders, tremors, 
hindleg clasping, and stereotypic behaviors (Sathasivam et al., 1999).  The typical age of onset is 
8 weeks for the R6/2 mice with death occurring at about 12 weeks and between 4-5 months for 
the R6/1 mice with an early death of about one year.  The brains of 12 week old R6/2 mice have 
been shown to be 20% smaller then age-matched WT control mice and neurogeneration 
occurring at about 14 weeks of age.  R6/1 mice show similar signs of HD as those found in R6/2 
mice accept on a slower time scale. 
b. Rats 
Using rat models of HD allows for a mammalian model that more closely related to 
humans.   Rat models allow for the study of HD over a longer time frame, which will give a 
better idea of the disease progression as it occurs in an adult opposed to in children.  Until 
recently the only rat models for HD came from the use of mitochondrial toxins to create similar 
characteristics to those of HD patients, now there is transgenic rat model available made with the 
a portion of the human htt gene.   
The HDtg rat is the first transgenic rat model for a neurodegenerative brain disorder.  The 
HDtg rat model is similar to the R6/2 mouse model in that is uses a truncated version of the htt 
gene.   It contains a strand of cDNA that corresponds to a 51 CAG repeat.  The length of the 
repeat corresponds to an adult onset of HD (von Hörsten et al., 2003).  The HDtg rats show 
signs of HD similar to those found in humans.  These rats have shown an age dependent 
impaired striatal function including enlarged striatal ventricles and atrophy (Kantor et al., 2006).  
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The HDtg rats also show an age dependent, genotype dependent decrease in behavior including 
signs of choriec movements (Cao et al., 2006).  
Several chemically-induced models of HD have been developed to mimic the 
neurological and behavioral features of human HD.  Glutamate analogues such as kainate and 
quinolinate and mitochondrial toxins such as amino-oxyacetate, rotenone, MPP+, malonate, 3-
acetylpyridine and 3-nitropropionic acid (3NP) are among some of the compounds used with 
3NP being the most extensively used (McGeer and McGeer, 1976, Beal et al., 1986, Beal et al., 
1993a, Beal et al., 1993b, Brouillet et al., 1993, Schulz and Beal, 1994).  3NP is an irreversible 
inhibitor of the tricarboylic acid cycle which leads to the inhibition of the mitochondrial 
respiratory chain complex II (Alston et al., 1977, Coles et al., 1979).  The administration of 3NP 
causes degeneration of putamen and caudate nucleus which causes severe neurological behaviors 
like those found in HD (Brouillet et al., 2005).       
Rats treated with 3NP show symptoms similar to those found in HD patients.  Chronic 
3NP treatment causes a lesion in the striatum when administered to rats and mice.  3NP-treated 
rats have also been shown to have a decrease in DA release in vivo and a diminished locomoter 
activity, characteristics that are present in R6/1 and R6/2 mice (Johnson et al., 2006, Johnson et 
al., 2007, Kraft et al., 2009, Ortiz et al., 2011a). 
D. Oxidative Stress and Methione Sulfoxide Reductase Mice(MsrA-/-) 
Many neurological diseases, such as Parkinson‟s disease, HD, and Lou Gehrig‟s disease 
have been linked with an increase in reactive oxidative species which causes an increase in the 
degree of cell oxidative stress found in the brain (Cohen, 1983, Perez-Severiano et al., 2004, 
Patten et al., 2010).  Reactive oxygen species can cause post-translational modifications that alter 
24 
 
protein functions and in most cases these modifications cannot be reversed.  Methionine 
sulfoxide (MetO) modifications though are an exception and can be reversed by the methionine 
sulfoxide reductase (Msr) system.  The Msr system consists of two parts MsrA which reduces S-
MetO and MsrB which reduces R-MetO (Moskovitz, 2005).  The Msr system has a role in 
antioxidant defense, may prevent irreversible protein damage, and regulate protein function 
(Moskovitz et al., 1995, Moskovitz et al., 1997, Moskovitz et al., 2001).  An over-expression of 
MsrA has been shown to provide protection from oxidative stress toxicity (Moskovitz et al., 
1998).  The MrsA 
-/-
 knockout mouse is hypersensitive to oxidative stress and expresses brain 
pathologies associated with neurodegenerative diseases (Moskovitz et al., 2001).   
The MrsA
-/-
 mice show characteristics that would suggest dysfunction of the 
dopaminergic pathway.  Using FSCV it has been shown that MsrA mice have an increase in DA 
release when compared to age-matched wild-type mice, increased reserve pool DA and the DA 
content is higher in MsrA
-/-
 mice (Oien et al., 2008, Ortiz et al., 2011b).  MrsA
-/-
 also show a lack 
of locomotor activity, abnormal gait, and are less responsive to AMPH (Oien et al., 2008).   
The oxidative stress mouse model and the various HD rodent models allow for the further 
study of the dopaminergic pathway and the affects that is has on neurodegenerative disease 
pathways.  By getting a better understanding of the dysfunction in these animal models could 
potentially allow for future pharmalogical intervention.  
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Chapter 2: DA Release and Uptake in HD 
The DA release and uptake has been shown to be inhibited in the R6/2 mouse model.  Using 
FSCV an age dependent study showed that as the age progresses an inhibition in the DA release 
was shown.  At six weeks of age there was not a significant decrease in DA release but at 12 
weeks of age the DA release was inhibited.  Microdialysis studies also showed a decrease in DA 
release in R6/1 mice.  The following three papers published from our lab look at the DA release 
in R6/1 mice, HDtg rats, and in 3NP treated rats. 
A. Impaired Dopamine Release and Uptake in Huntington’s Disease 
Model Mice 
Huntington‟s disease (HD) is a progressive, neurodegenerative movement disorder.  
Here, we used fast-scan cyclic voltammetry to measure dopamine release and uptake in striatal 
brain slices from R6/1 HD model mice.  Peak dopamine release ([DA]max) was significantly 
diminished in R6/1 mice compared to age-matched wild-type control mice at 24 weeks of age 
(52.2% of wild-type), but not at 10 or 16 weeks of age.  Similarly, dopamine released per locally 
applied electrical stimulus pulse ([DA]p), which is [DA]max corrected for uptake and electrode 
performance, was also diminished in R6/1 mice at this age (43.1% of wild-type).  Moreover, 
Vmax, the maximum rate of dopamine uptake, obtained by modeling the stimulated release plots, 
was decreased at 16 and 24 weeks of age in R6/1 mice (51.0 and 48.0% of wild-type, 
respectively).  Thus, impairments in both dopamine release and uptake appear to progress in an 
age-dependent manner in R6/1 mice. 
Introduction 
 
Huntington‟s disease (HD) is an autosomal dominant neurodegenerative disorder caused 
by an expanded CAG repeat on the gene that encodes the huntingtin (htt) protein (The 
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Huntington's Disease Collaborative Research Group, 1993).  This expansion results in the 
expression of an extended polyglutamine segment which ultimately causes striatal degeneration, 
mood disturbances, choreic movements, and cognitive dysfunction (Bates et al., 2002).  
Dopaminergic innervation projecting from the substantia nigra pars compacta to the striatum 
exerts influence over the control of intentional movement (Kandel et al., 2000).  Therefore, it has 
been suggested that impairments in dopamine release may contribute to the progressive motor 
phenotype that is characteristic of HD (Johnson et al., 2006, Kraft et al., 2009, Ortiz et al., 2010). 
Several genetically engineered mouse strains that model HD have been used to 
investigate dopaminergic system alterations.  Of these, the R6/2 mouse, which possesses exon 1 
of the human huntingtin (htt) protein with about 144 CAG repeats (Mangiarini et al., 1996, 
Davies et al., 1997), has been the most extensively studied.  R6/2 mice express a progressive, 
overt behavioral phenotype that starts between 9 to 11 weeks of age and typically die at 10 to 13 
weeks of age (Mangiarini et al., 1996, Davies et al., 1997).  In contrast, R6/1 mice, which also 
express a truncated version of the human htt, have a shorter CAG repeat length of about 116 
repeats.  Thus, overt phenotype onset begins later in life at 15 to 21 weeks of age with death 
occurring between 32 and 40 weeks of age (Mangiarini et al., 1996).   
Studies in which exocytotic DA release was directly measured in R6/1 mice have not 
been published to our knowledge; however, recent evidence raises that possibility that dopamine 
system function is indeed altered.  Increases in extracellular DA induced by ip injection of 
malonate, an excitotoxin, are less in R6/1 mice compared to WT control mice even though DA 
content, measured in striatal lysates, is unchanged (Petersén et al., 2002, Pineda et al., 2005)  
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Moreover, R6/1 mice exhibit a blunted locomotor response to amphetamine, but not 
apomorphine, indicating that presynaptic dysfunction of the dopaminergic system is responsible 
for these behavioral alterations (Pineda et al., 2005).  Nevertheless, it is not known if DA release 
and uptake are altered.  A clear assessment of DA release and uptake dynamics in R6/1 mice and 
other HD model rodents is important because underlying genetic differences, such as CAG 
repeat length, may alter nervous system function differently between strains.     
In this work, we used FSCV to investigate DA release and uptake in striatal brain slices 
harvested from R6/1 mice.  FSCV is useful in this case because its good temporal resolution (10 
measurements/s as applied in this work) allows for DA release and uptake to be measured as 
separate processes. 
   Methods 
Animals.  R6/1 [CBy.Cg-Tg(HDexon1)61b] and wild-type mice were purchased from Jackson 
Laboratories (Bar Harbor, Maine) and were housed at the University of Kansas animal care unit 
prior to use.  Food and water were provided ad libitum and a 12-hour light-dark cycle was used.  
All animal procedures were approved by the University of Kansas Institutional Animal Care and 
Use Committee.       
Brain Slice Preparation.  Brain slices were prepared, as previously described, from R6/1 and 
WT mice at 10, 16, and 24 weeks of age (Johnson et al., 2006).  Mice were anesthetized by 
isoflurane inhalation and then decapitated.  The brain was immediately removed and placed in 
ice cold artificial cerebrospinal fluid (aCSF) consisting of 126 mM NaCl, 2.5 mM KCl, 1.2 mM 
NaH2PO4, 2.4 mM CaCl2, 1.2 mM MgCl2, 25 mM NaHCO3, 20 mM HEPES, and 11 mM D-
Glucose with a pH of 7.4.  The aCSF was oxygenated by bubbling 95% O2/5% CO2 gas into the 
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aCSF throughout the experiment.  After the brain was removed from the skull, the cerebellum 
was sliced off and the brain was mounted on an aluminum block.  Coronal slices, 300 µm thick, 
were made using a vibratome slicer (Leica, Wetzlar, Germany).  A single brain slice was placed 
in the superfusion chamber, which was maintained at 34°C and had a continuous flow of aCSF at 
a rate of 2 mL/min.  Each brain slice was equilibrated in the superfusion chamber for 60 minutes 
prior to obtaining measurements.   
DA release in brain slices.  Carbon-fiber microelectrodes were fabricated as previously 
described (Kraft et al., 2009).  Briefly, a single 7 μm diameter carbon-fiber (Goodfellow 
Cambridge Ltd, Huntingdon, U.K.) was aspirated through a glass capillary tube (1.2 mm outer 
diameter, 0.68 mm inner diameter, 4 inches long, A-M Systems, Inc. Carlsborg, WA, USA), and 
then the capillary tube was pulled using a heated coil puller (Narishige International USA, Inc., 
East Meadow, NY).  After the electrodes were trimmed to about 25 μm from the glass seal they 
were further insulated with epoxy resin (EPON resin 815C, EPIKURE 3234 curing agent, 
Miller-Stephenson, Danbury, CT, USA), and then cured at 100C for 1 h.  The electrodes were 
backfilled with 0.5 M potassium acetate in order to provide an electrical connection between the 
carbon fiber and an inserted silver wire.   
A triangular waveform was applied to the carbon-fiber working electrode.  The potential 
was held -0.4 V, increased to +1.0 V, and then scanned back to -0.4 V at a scan rate of 300 V/s 
and an update rate of 60 Hz.  A headstage amplifier (UNC Chemistry Department Electronics 
Design Facility, Chapel Hill, NC) was interfaced with a computer via a breakout box and custom 
software provided by R.M. Wightman and M.L.A.V. Heien, University of North Carolina, 
Chapel Hill.  A chlorided silver wire was used as an Ag/AgCl reference electrode.  The carbon 
fiber microelectrode was inserted to a depth of 100 µm in the dorsolateral caudate-putamen 
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region of the striatum between the prongs of a bipolar stimulation electrode (Plastics One, 
Roanoke, VA), which was separated by a distance of 200 μm.  A single electrical stimulus pulse 
at 60Hz was applied to the brain slice and the current was then measured at the peak oxidation 
potential for dopamine (about +0.6V versus Ag/AgCl reference electrode).  Working electrodes 
were calibrated with dopamine standards of known concentration in a flow cell before and after 
each use.  The average of the pre- and post-calibration measurements was used as the calibration 
factor.   
DA release measurements were collected in four locations of the dorsal lateral striatum in 
each brain slice.  Each release plot was then modeled based on Michaelis-Menten kinetics, as 
previously described in Johnson et al., 2006 (Johnson et al., 2006) to determine [DA]p, the peak 
DA release per electrical stimulus pulse, and Vmax, the maximum uptake rate of DA by the 
dopamine transporter.  [DA]p is distinguished from [DA]max, the peak DA release amplitude, 
because it is corrected for uptake and electrode performance.  Values obtained from the four 
sampling points were used to obtain an average value for each slice.   
Statistics.  All values are represented as the average ± SEM, where N = the number of brain 
slices.  Comparisons were made using a Student‟s t test.  
Results 
 DA release was measured using a single pulse stimulation and FSCV at carbon fiber 
microelectrodes in brain slices harvested from R6/1 and WT mice at 10, 16, and 24 weeks old 
(Fig. 1A).  Cyclic voltammograms (CVs) obtained at the highest point of stimulated release were 
used to verify that the analyte detected was DA.  The average values of [DA]max (Fig. 1B) were: 
10 weeks of age, 0.82 ± 0.17 µM (R6/1; n = 9 ) and 0.89 ± 0.14 µM (WT; n = 8); 16 weeks of 
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age, 1.03 ± 0.17 µM (R6/1, n = 16) and 1.50 ± 0.23 µM (WT, n = 8); and 24 weeks of age, 0.48 
± 0.13 µM (R6/1, n = 8) and 0.92 ± 0.14 µM (WT, n = 15).  Peak stimulated DA release 
([DA]max) was less in R6/1 mice than WT control mice at 24 weeks of age (p < 0.05).   
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Fig 1.  Stimulated DA release is diminished in older R6/1 mice compared to age-matched WT 
mice. (A) Representative plots of stimulated DA release in R6/1 and WT striatal brain slices.  
The time of stimulated release is indicated by the arrow.  (B) Bar graph of average [DA]max 
measured in striatal slices from R6/1 and WT control mice at 10, 16, and 24 weeks of age.  
[DA]max was significantly diminished in R6/1 mice at 24 weeks of age (*p<0.05, n= 8 R6/1 and 
15 WT slices).    
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The stimulated release plots were modeled, using a simplex-based computer program, to 
determine [DA]p, the peak extracellular DA concentration (per stimulus pulse) corrected for 
uptake and electrode performance (Fig. 2A).  Similar to the trend observed with [DA]max, [DA]p 
was found to decrease as the age of the mice increased (Fig. 2B).  The average values of [DA]p 
were: 10 weeks of age, 1.58 ± 0.44 µM (R6/1; n = 9 ) and 1.67 ± 0.30 µM (WT; n = 8); 16 weeks 
of age, 1.45 ± 0.21 µM (R6/1, n = 16) and 2.13 ± 0.36 µM (WT, n = 8); and 24 weeks of age, 
0.66 ± 0.14 µM (R6/1, n = 8) and 1.53 ± 0.27 µM (WT, n = 15).  By 16 weeks of age, [DA]p, 
although not significant, appeared to be less in R6/1 mice than in WT mice.  At 24 weeks of age, 
the R6/1 mice released significantly less (p < 0.05) DA than age-matched WT control mice.  
Additionally, R6/1 mice released less DA at 10 weeks of age than R6/1 mice at 24 weeks of age 
(p < 0.005). 
The data obtained from the aforementioned modeling operation also provided us with 
Vmax, which describes the maximum rate of uptake by the DAT and is directly proportional to the 
number of functioning DAT protein molecules.  The average values of Vmax were:  10 weeks of 
age, 10.5 ± 4.3 µM/s (R6/1; n = 9 ) and 9.0 ± 2.3 µM/s (WT; n = 8); 16 weeks of age, 4.12 ± 
0.55 µM/s (R6/1, n = 16) and 8.08 ± 1.99 µM/s (WT, n = 8); and 24 weeks of age, 3.13 ± 0.98 
µM/s (R6/1, n = 8) and 6.52 ± 1.74 µM/s (WT, n = 15).  Compared to age-matched WT controls, 
Vmax was significantly decreased (p < 0.05) in slices from R6/1 mice at 16 and 24 weeks of age 
(Fig. 2C).   
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Fig. 2.  DA release per pulse [DA]p and Vmax are decreased in older R6/1 mice compared to age-
matched WT mice.  (A) Representative plots and modeled curves of stimulated DA release in an 
R6/1 slice and a WT slice.  (B) The [DA]p is inhibited in 24 week old R6/1 mice when compared 
to WT mice of the same age (*p<0.05, n= 8 R6/1 and 15 WT slices) but not in 10 and 16 week 
old mice. (C) Vmax is inhibited in 16 and 24 week old R6/1 mice when compared to age-matched 
WT mice (*p<0.05; 16 weeks: n= 16 R6/1 and 8 WT slices, 24 weeks: n= 8 R6/1 and 15 WT 
slices). 
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Discussion 
In this study, we examined the DA release and uptake in R6/1 mice at 10, 16, and 24 
weeks of age.  [DA]p and Vmax were determined from the best-fit parameters that were used in 
modeling the stimulated release plots.  These results show that [DA]max, [DA]p, and Vmax 
decrease progressively over time compared to age-matched WT mice.   
 Our initial results indicated that [DA]max, the peak concentration of evoked DA detected 
at the electrode, progressively decreased in R6/1 mice as they aged.  Therefore, we modeled the 
plots to determine [DA]p and Vmax.  [DA]p may be considered a more reliable measure of how 
much DA is released per electrical stimulus pulse because it takes into account DA uptake and 
electrode performance.  [DA]p was significantly diminished by 24 weeks of age.  Complimentary 
to our results are previous microdialysis studies which show that basal DA levels and malonate-
induced DA efflux are diminished in the R6/1 striatum (Petersén et al., 2001) even though 
striatal DA content is unchanged at either 16 weeks (Petersén et al., 2001) or 30 weeks of age 
(Pineda et al., 2005).  Therefore, the [DA]p values obtained using FSCV allow us to make the 
more specific interpretation that the ability of dopaminergic terminals to release DA by 
exocytosis is progressively impaired in R6/1 mice.  These findings are similar to those found in 
R6/2 mice (Johnson et al., 2006); however, consistent with having a shorter CAG repeat length, 
this impairment progresses more slowly with age. 
In addition to DA release, values of Vmax were decreased in R6/1 mice compared to WT 
control mice at 16 and 24 weeks of age.  Previous labeling experiments indicate that striatal DAT 
expression is similar in R6/1 and WT mice.  Thus, decreased uptake is likely not related to a 
decrease in the number of DAT protein molecules.  This determination is important because DA 
44 
 
uptake by the DAT is known to follow Michaelis-Menten uptake kinetics and, therefore, the 
equation Vmax = kcat[E]t is obeyed, where kcat is a rate constant and [E]t represents the total 
enzyme concentration (Mathews and van Holde, 1996), in this case DAT.  Thus, since [E]t is 
likely unchanged, the difference in uptake may represent a modification of the transporter.  It is 
also important to note that these findings differ from those obtained in R6/2 mice, in which Vmax 
was unchanged throughout the entire course of phenotype progression.  Therefore, age, coupled 
with the HD mutation, apparently also plays an important role in the changes in Vmax.   
In conclusion, this report reveals key malfunctions in DA release in R6/1 mice, and also 
shows that the DA uptake kinetics of R6/1 differ from those of R6/2 mice, a popularly used 
genetic HD model.  These findings reveal potentially important considerations for researchers 
studying DA system function in these HD models.       
B. Enhanced Striatal Dopamine Stores in Rats Treated with 3-
Nitropropionic Acid 
Fast-scan cyclic voltammetry at carbon-fiber microelectrodes was used to measure electrically-
evoked dopamine release and uptake in the dorsolateral caudate of striatal brain slices harvested 
from rats treated with 3-nitropropionic acid.  Both release and uptake in this brain region were 
unchanged in 3-nitropropionic acid-treated rats, compared to sham controls.  However, further 
investigation indicated that reserve pool dopamine content was enhanced ~112% by 3-
nitropropionic acid treatment, suggesting that a compensatory effect, in which the dopamine 
reserve pool is augmented, occurs in this brain region.  
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Introduction 
Huntington‟s disease (HD) is a familial neurodegenerative disorder caused by an 
expanded CAG repeat sequence on the gene that encodes the huntingtin protein (Huntington‟s 
Disease Collaborative Research Group, 1993).  HD is characterized by cognitive dysfunction, 
choreic movements, and striatal degeneration (Bates et al., 2002).  Previous evidence suggests 
that impaired striatal dopamine (DA) release in transgenic HD mice contributes to the 
progressive motor phenotype. (Abercrombie and Russo, 2002, Hickey et al., 2002, Petersén et 
al., 2002, Johnson et al., 2006, Johnson et al., 2007).   
   A number of chemical compounds, administered locally and systemically, have been 
applied to various strains of rat in attempts to replicate neurological and behavioral features of 
human HD.  These compounds include kainate (McGeer and McGeer, 1976), malonate (Beal et 
al., 1993), 3-acetylpyridine (Schulz and Beal, 1994), and 3-nitropropionic acid (3NP) (Beal et al., 
1993, Brouillet et al., 1993), to name a few.  Of these and other chemical treatments, the 
application of 3NP is among the most extensively used to model HD.  Previous work has 
suggested that DA release, evoked by stimulation of the medial forebrain bundle (mfb) and 
measured in the dorsomedial caudate putamen with fast scan cyclic voltammetry (FSCV), is 
diminished in the dorsomedial striatum of 3NP treated rats.  The subsequent finding that DA 
content in striatal lysates was unaffected by 3NP treatment prompted us to probe further the 
amount of striatal DA stored in the reserve pool (Kraft et al., 2009). 
In this work, we used FSCV to measure locally-stimulated DA release in striatal brain 
slices from 3NP-treated rats.   Interestingly, DA release in 3NP-treated rats was unchanged 
compared to sham controls.  Moreover, DA uptake appeared to be unaffected by 3NP treatment.  
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However, measurements of DA efflux, induced by amphetamine (AMPH) and obtained after 
inhibiting DA synthesis, suggest that an increased number of DA molecules are held in reserve in 
3NP rats compared to sham-treated rats. 
Materials and Methods 
Animal Procedures 
The 3NP experiments were carried out on 12 week old male Lewis rats (300-350 g), 
obtained from Charles River Laboratories, Inc. (Wilmington, MA).  Rats were anesthetized with 
a mixture containing ketamine hydrochloride (56.25 mg/kg), xylazine hydrochloride (2.85 
mg/kg), and acepromazine maleate (0.56 mg/kg), injected im.  An incision was made between 
the shoulder blades and a 2 mL Alzet osmotic pump (2ML1; delivering 10 uL/hr for up to 7 
days; Durect Corporation, Cupertino, CA) containing 3NP was positioned subcutaneously.  The 
final concentration of 3NP in the pump was adjusted according to the weight of the rat on the day 
of surgery, so that 54 mg/kg day was delivered.  Rats were continuously infused with 3NP for 5 
days.  Sham controls rats underwent the same surgical procedure without the implantation of the 
Alzet pump.  All rats were provided with food and water ad libitum in a temperature/humidity- 
controlled environment on a 12-h light/dark cycle.  All animal procedures were approved by the 
University of Kansas Institutional Animal Care and Use Committee.    
Brain Slice Preparation 
Rats were anesthetized by isoflurane inhalation and decapitated.  The brain was 
immediately removed and placed in ice cold artificial cerebrospinal fluid (aCSF).  The aCSF 
consisted of 126 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 2.4 mM CaCl2, 1.2 mM MgCl2, 25 
mM NaHCO3, 20 mM HEPES, and 11 mM D-Glucose.  The pH was adjusted to 7.4 using 5 M 
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HCl and was continuously saturated with 95% O2/5% CO2.  The cerebellum was sliced off with a 
razor blade and then the brain was glued onto an aluminum block.  Coronal slices, 300 μm thick, 
were made using a vibratome.  Brain slices containing the striatum were stored in ice cold aCSF.  
A single slice was placed in a superfusion chamber that was maintained at 34°C and had a 
continuous flow of aCSF (2 mL/min).  Each brain slice was equilibrated for 60 minutes prior to 
obtaining measurements.  To apply αMPT and AMPH, aCSF containing the drugs was 
maintained in a separate reservoir and introduced through a three-way valve. 
DA Release in Brain Slices 
For a typical experiment, a triangular waveform, starting at -0.4 V, increasing to +1.0 V, 
and then scanning back down to -0.4 V, was applied to a carbon fiber microelectrode.  A scan 
rate of 300 V/s and a cyclic voltammogram (CV) collection rate of 10 CVs/s was used.  DA was 
evoked by application of either a single electrical stimulus pulse or a series of 120 pulses, with 
each pulse having a duration of 4 ms and a current of 350 μA.  A headstage amplifier (UNC 
chemistry department electronics design facility, Chapel Hill, NC) was interfaced with a 
computer via a breakout box and custom software provided by R.M. Wightman and M.L.A.V. 
Heien, University of North Carolina, Chapel Hill.  An Ag/AgCl reference electrode was used.  
The carbon fiber was inserted 100 µm into the dorsolateral caudate-putamen region of the 
striatum between the prongs of a bipolar stimulation electrode (Plastics One, Roanoke, VA).  DA 
release was measured at four locations in the dorsal lateral striatum and averaged to obtain a 
single value for each slice.  The values obtained for each slice were then combined to obtain an 
average value for each animal.  Working electrodes were calibrated with DA standards of known 
concentrations in a flow cell before and after each use.  The average of the pre- and post-
calibration values was used as the calibration factor.   
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Reserve pool DA was measured using previously established procedures (Ortiz et al., 
2010).  Briefly, a single pulse stimulus was applied every five minutes until peak stimulated DA 
release remained constant between stimulations.  Next, 50 µM aMPT was added to the aCSF, 
while continuing to stimulate the brain slice every 5 minutes, until DA release disappeared.  The 
aMPT/aCSF solution was then changed to also contain 20 µM AMPH and the peak amplitude of 
AMPH-induced DA efflux ([DA]AMPH), which occurred after about 25 minutes, was measured.  
Data Analysis 
Single pulse measurements taken in slices from the 3NP-treated rats and sham controls 
were modeled using software, designed by P. A. Garris, Illinois State University, that 
incorporates a simplex algorhythm in order to determine [DA]p and Vmax.  [DA]p is the peak DA 
release per electrical stimulus pulse corrected for uptake and electrode performance.  Vmax 
corresponds to the maximum rate of DA uptake and is directly proportional to the number of 
functioning membrane-bound DAT protein molecules.  The application of this software to data 
obtained in rodents that model HD has been described previously (Johnson et al., 2006, Kraft et 
al., 2009). 
For statistical comparisons, GraphPad Prism (version 4.03) statistical software was used.  
Data are expressed as mean +/- SEM.  Comparisons were assessed by Student‟s t-test (unpaired).  
A probability level of 5% (p < 0.05) was considered significant. 
Results and Discussion 
Striatal Dopamine Release and Uptake  
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Voltammetric measurements of DA release in brain slices were obtained during local 
electrical stimulation (120-pulses applied over a 2-s period); thus, differences in release should 
be attributed to changes that have occurred to dopaminergic terminals as a result of 3NP 
treatment.  However, peak DA release (Figure 1) did not significantly differ between the 3NP-
treated and sham rats (p > 0.05, 3NP-treated, 3.71 ± 0.46 µM, n = 5 rats; sham, 3.33 ± 0.42 µM, 
n = 5 rats), suggesting that treatment did not alter the ability of dopaminergic terminals in the 
dorsolateral caudate to release DA.  Moreover, these results suggest that the motor syndrome 
associated with the 3NP model may also be caused by neurological dysfunction in other brain 
regions.  It is important to note that the dorsomedial caudate lacked structural integrity (fell apart 
upon slicing) in these experiments, making FSCV measurements in this brain region impractical. 
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Figure 1. 
Striatal DA release is unchanged in 3NP-treated rats compared to sham control rats.  DA release 
was evoked by local application of 120-pulse electrical stimuli, indicated by bars under the 
release plots.  (A) Representative plots and CVs obtained by FSCV at carbon-fiber 
microelectrodes are shown for 3NP-treated and sham rats.  (B) Stimulated DA release was 
unchanged between the 3NP-treated and sham control rats.  The average DA release values for 
the 3NP-treated was 3.71 ± 0.46 µM, (n = 5 rats); and the sham rats had an average release of 
3.33 ± 0.42 µM (n = 5 rats).   
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To determine if DA uptake is altered in brain slices from 3NP rats, plots of DA release, 
evoked by single stimulus pulses, were obtained.  These plots were modeled, based on 
Michaelis-Menten kinetics, to determine Vmax and [DA]p.  This modeling operation has been 
described previously (Johnson et al., 2006).  Vmax is directly proportional to the total number of 
functioning DAT protein molecules and [DA]p is DA released per stimulus pulse, corrected for 
uptake and electrode performance.  Vmax and [DA]p were both unchanged between the 3NP-
treated and sham rats, indicating that both release and uptake are unaffected by 3NP treatment 
(Figure 2).   
52 
 
 
Figure 2.  
DA release plots obtained by application of a single electrical stimulus pulse were modeled to 
determine [DA]p and Vmax in 3NP-treated and sham-treated control rats.  (A) The experimental 
data (open circles) for the Sham and 3NP-treated rats in comparison with the modeled curves 
(solid line).  (B) [DA]p was unchanged between the sham and 3NP-treated rats (p > 0.05; n = 5 
sham and 3NP-treated rats).  The average [DA]p for the sham rats is 1.60 ± 0.29 µM and 1.52 ± 
0.16 µM.  (C) Vmax was unchanged between the 3NP-treated rats and the sham-treated control 
rats (p > 0.05).  The average Vmax for the sham rats was 7.66 ± 2.28 µM/s (n = 5 rats) and the 
3NP-treated rats was 8.36 ± 1.52 µM/s (n = 5 rats). 
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These results also indicate that the number of functioning DAT protein molecules was 
unchanged, and that the vesicular release machinery was functioning normally.  It is interesting 
that in vivo DA release, evoked in anesthetized 3NP-treated rats by stimulation of the 
dopaminergic pathway at the medial forebrain bundle (mfb) and measured in the dorsomedial 
striatum with FSCV (Kraft et al., 2009), was diminished.  Thus, it is possible that a mechanism is 
in place in this brain region that could help preserve normal levels of DA release in the 
dorsolateral region.   
The sub-second temporal resolution of FSCV allows for the measurement and analyses of 
specific DA release events, whereas microdialysis can show only slower changes in extracellular 
DA levels.  Thus, the FSCV measurements in this work provide a more direct measure of how 
well presynaptic terminals release dopamine by exocytosis and take it back up through the DAT.  
To our knowledge, this work and Kraft et al. (2009) are the only studies in which DA release and 
uptake were measured at high temporal resolutions in 3NP-treated animals.   
Reserve Pool DA Levels in 3NP Rats 
 The DA reserve pool is thought to mobilize during periods of prolonged synaptic activity 
(Neves and Lagnado, 1999, Zucker and Regehr, 2002, Rizzoli and Betz, 2005).  To identify the 
impact of 3NP treatment on reserve pool DA, brain slices were exposed to 50 µM αMPT, which 
inhibits tyrosine hydroxylase, the rate limiting enzyme in DA synthesis (Figure 3A).  A single 
electrical stimulus pulse was then applied every five minutes until there was no longer DA 
release.  At this point, DA in the extracellular space and in releasable vesicles was depleted, 
leaving only DA stored in the reserve pool.  After release disappeared, 20 µM AMPH was added 
to the aCSF perfusion solution and the resulting DA efflux was measured over the course of 25 
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minutes to determine [DA]AMPH.  AMPH is a competitive DAT inhibitor that empties vesicles 
and induces reverse transport from terminals, allowing for the quantitative measurement of 
internal DA stores.  Thus, upon the addition of AMPH both cytosolic and vesicular DA exit the 
terminals by reverse transport through the DAT into the extracellular space (Sulzer et al., 1995, 
Floor and Meng, 1996, Jones et al., 1998).  [DA]AMPH in 3NP-treated rats was greater than that of 
the sham control rats (Figure 3B; p < 0.05; 3NP-treated, 16.7 ± 2.5 µM, n = 3 rats; sham, 7.86 ± 
1.79 µM, n = 5 rats). 
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Figure 3. 
AMPH-induced efflux after treatment with αMPT is greater in 3NP-treated rats than in WT rats.  
(A) Slices were treated with αMPT until the stimulated DA release peak disappeared.  Slices 
were then treated with AMPH and [DA]AMPH was measured.  (B) [DA]AMPH was significantly 
increased in slices from 3NP-treated rats compared to those from age-matched sham control 
mice (*p < 0.05).  The average [DA]AMPH in 3NP-treated rats was 16.68 ± 2.49 µM (n = 3 rats) 
and 7.86 ± 1.79 µM (n = 5 rats) in sham control rats. 
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  Our recent evidence suggests that the 120-pulse stimulation regimen evokes the release 
of DA from multiple stores within presynaptic terminals in striatal brain slices (Ortiz et al., 
2010).  Therefore, speculate that 3NP treatment induced the occurrence of a compensatory effect, 
in which the amount of DA within the reserve pool was boosted.  One of the more common 
models of vesicle distribution within presynaptic terminals identifies vesicles as belonging to one 
of three groups (Rizzoli et al., 2005):  the readily releasable pool (RRP), the recycling pool, and 
the reserve pool.  The RRP undergoes exocytosis upon mild stimulation, and is then replenished 
by the recycling pool (Neves and Lagnado, 1999).  Reserve pool vesicles, which make up ~80-
90% of total vesicles (Zucker et al., 2002; Rizzoli et al., 2005), are thought to aid in 
neurotransmission during periods of prolonged synaptic activity.  Therefore, striatal dysfunction 
in HD could potentially arise from impairments in the mobilization or storage of reserve pool 
DA.  We have previously shown that R6/2 mice have fewer vesicles in the reserve pool then wild 
type control mice (Ortiz et al., 2010).      
These DA efflux measurements reveal that 3NP-treated rats had an increased amount of 
reserve pool DA.  Although the underlying causes of this increase have not been identified, a 
possible mechanism could be the uptake of DA released by the degeneration of surrounding 
neurons caused by 3NP treatment (Ouary et al., 2000, El Massioui et al., 2001, Brouillet et al., 
2005).  This enhanced reserve pool may help supply the dopaminergic terminals with sufficient 
DA-filled vesicles for a normal level of release.  Alternatively, these enhanced DA levels may 
also increase oxidative stress by increased production of hydroxyl radicals (Pandey et al., 2009).     
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In conclusion, our studies reveal an inherent difference in DA storage in the dorsolateral 
caudate of 3NP-treated rats compared with sham-treated rats.  These differences may arise from 
an enhancement of the DA reserve pool in 3NP-treated rats, and should be considered when 
using chemically-induced animal models to study DA-related mechanisms.       
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Chapter 3: Dopamine Reserve Pools in Huntington’s Disease 
 Using FSCV it has previously been shown that there is a decrease in DA release in rodent 
models of Huntington‟s disease including R6/1 mice, R6/2 mice and 3NP treated rats.  This 
chapter explores the DA reserve pools in the most extensively studied HD mouse model the R6/2 
mice.   
A. Dysregulation of intracellular dopamine stores revealed in the R6/2 
mouse striatum 
Huntington‟s disease is a fatal, neurodegenerative movement disorder characterized by 
preferential and extensive striatal degeneration.  Here, we used fast-scan cyclic voltammetry to 
study the mobilization and efflux of reserve pool dopamine in striatal brain slices from 
Huntington‟s disease model R6/2 mice.  When applying stimulus trains of 120 pulses, evoked 
dopamine release in wild-type slices was greater than that in R6/2 slices at the higher frequencies 
(50 and 60 Hz).  To quantify cytosolic and reserve pool dopamine levels, amphetamine-induced 
dopamine efflux was measured after pre-treatment with either tetrabenazine or alpha-methyl-p-
tyrosine.  Slices from 12-week old R6/2 mice released less dopamine than slices from wild-type 
mice, while no difference was noted in slices from 6-week old mice.  Dopamine efflux currents, 
normalized against stimulated release currents, suggest an enhancement of cytosolic dopamine 
levels in the R6/2 striatum.  The vesicular release of reserve pool dopamine, mobilized by 
treatment with cocaine, was shorter lived in R6/2 slices compared to wild-type slices even 
though peak dopamine release was the same.  Moreover, the number of dopamine reserve pool 
vesicles in R6/2 mice was less than half of that in wild-type.  Therefore, our data suggest that 
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R6/2 mice have fewer dopamine reserve pool vesicles, but have enhanced cytosolic dopamine 
levels.  
 
 
Introduction 
 
Huntington‟s disease (HD) is an autosomal dominant neurodegenerative movement 
disorder caused by an expanded CAG repeat on the gene that encodes the huntingtin protein 
(htt).  HD is characterized by mood disturbances, choreic movements, cognitive dysfunction, and 
degeneration of the striatum (Bates et al., 2002).  Recent evidence indicates that impaired striatal 
dopamine (DA) release in HD rodent models contributes to the progressive motor phenotype.  
This evidence includes:  in vivo microdialysis studies in which DA levels in R6/1 and R6/2 mice 
were lower than that of wild type (WT) controls (Abercrombie and Russo, 2002; Petersén et al., 
2002); locomotor measurements in which R6/2 mice had a blunted response to cocaine (COC) 
and methamphetamine (METH; Hickey et al., 2002; Johnson et al., 2006); and stimulated DA 
release measurements taken using fast-scan cyclic voltammetry (FSCV) in which release in R6/2 
brain slices was impaired (Johnson et al., 2006; Johnson et al., 2007).  Furthermore, 
amperometry data collected from adrenal chromaffin cells suggest that quantal release of 
catecholamines is diminished in R6/2 mice (Johnson et al., 2007).  Nevertheless, specific 
mechanisms underlying presynaptic DA release impairments in striatal brain tissue have not yet 
been thoroughly investigated. 
One potential mechanism of striatal dysfunction in R6/2 mice involves the mobilization 
of reserve pool DA.  Vesicles containing DA are believed to be partitioned into three distinct 
pools.  These pools include the readily releasable pool (RRP), which undergoes exocytosis upon 
mild stimulation, the recycling pool, which is mobilized to replace RRP vesicles, and the reserve 
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pool, which is thought to be mobilized during periods of prolonged synaptic activity (Neves and 
Lagnado, 1999; Zucker and Regehr, 2002; Rizzoli and Betz, 2005).  The reserve pool is the 
largest vesicle pool, consisting of ~80-90% of the total vesicles in the presynaptic terminal 
(Neves and Lagnado, 1999; Rizzoli and Betz, 2005).  It has been shown previously that a 
synapsin-dependent DA reserve pool can be mobilized by treatment with COC (Venton et al., 
2006).  Thus, not only does this study suggest a possible mechanism for the attenuated 
psychostimulatory effect of COC in R6/2 mice, but it also identifies a mechanism by which DA 
reserve pools can be pharmacologically manipulated.   
In this work, we investigated the neurochemical mechanisms that underlie striatal DA 
release impairments, which could potentially amplify phenotypical behavioral impairments 
observed in R6/2 mice (Carter et al. 1999).  We hypothesized that reserve pool DA is depleted in 
R6/2 mice.  To investigate this possibility, we used FSCV to measure amphetamine (AMPH) 
induced efflux and COC-induced vesicle mobilization of reserve pool DA in acute striatal slices 
from R6/2 and WT control mice.  Our results suggest not only that the number of vesicles 
present in the DA reserve pool of R6/2 mice is diminished, but also that cytosolic dopamine 
levels may be enhanced.     
Materials and Methods  
Drugs.  COC, αMPT, and AMPH were purchased from Sigma-Aldrich (St. Louis, MO).  
Tetrabenazine (TBZ) was a generous gift from Prof. Eric Floors, Department of Molecular 
Biosciences, University of Kansas. 
Animals.  R6/2 [B6CBA-Tg(HDexon1)62Gpb] and wild-type mice were purchased from Jackson 
Laboratories (Bar Harbor, Maine) and were housed at the University of Kansas animal care unit 
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prior to use.  Food and water were provided ad libitum and a 12-hour light-dark cycle was used.  
All animal procedures were approved by the Institutional Animal Care and Use Committee.       
Brain Slice Preparation.  Brain slices were prepared as previously described (Johnson et al., 
2006).  Briefly, mice were anesthetized by isoflurane inhalation and then decapitated.  The brain 
was immediately removed and placed in ice cold artificial cerebrospinal fluid (aCSF).  The aCSF 
consisted of 126 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 2.4 mM CaCl2, 1.2 mM MgCl2, 25 
mM NaHCO3, 20 mM HEPES, and 11 mM D-Glucose.  The pH was adjusted to 7.4.  During the 
brain slice harvesting procedure and during experimentation, the aCSF was continuously 
saturated with 95% O2/5% CO2.  The cerebellum was sliced off with a razor blade and then the 
brain was mounted on an aluminum block.  Coronal slices, 300 µm thick, were made using a 
vibratome slicer (Leica, Wetzlar, Germany).  Brain slices containing striata were stored in ice 
cold aCSF.  A single slice was placed in the superfusion chamber, through which aCSF, 
maintained at 34° C, flowed at a continuous rate of 2 mL/min.  Each brain slice was equilibrated 
in the superfusion chamber for 60 minutes prior to obtaining measurements.  To apply αMPT, 
TBZ, AMPH, and COC, aCSF containing these drugs was maintained in a separate reservoir and 
introduced through a three-way valve. 
DA release in brain slices.  Carbon-fiber microelectrodes were fabricated as previously 
described (Kraft et al., 2009), with minor changes.  Briefly, a single 7 μm diameter carbon-fiber 
(Goodfellow Cambridge Ltd, Huntingdon, U.K.) was aspirated through a glass capillary tube 
(1.2 mm outer diameter, 0.68 mm inner diameter, 4 inches long, A-M Systems, Inc. Carlsborg, 
WA, USA), which was pulled using a heated coil puller (Narishige International USA, Inc., East 
Meadow, NY).  Electrodes were trimmed to 25 μm from the glass seal, further insulated with 
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epoxy resin (EPON resin 815C, EPIKURE 3234 curing agent, Miller-Stephenson, Danbury, CT, 
USA), and then cured at 100C for 1 h.  Prior to experimentation, electrodes were backfilled with 
0.5 M potassium acetate in order to provide an electrical connection between the carbon fiber 
and an inserted silver wire.  No further treatment of the electroactive surface was performed. 
A triangular waveform, starting at -0.4 V, increasing to +1.0 V, and then scanning back to 
-0.4 V, was applied at the carbon-fiber working electrode.  A scan rate of 300 V/s was used with 
an update rate of 60 Hz for single pulse stimulations and 10 Hz for 120-pulse stimulations.   A 
headstage amplifier (UNC Chemistry Department Electronics Design Facility, Chapel Hill, NC) 
was interfaced with a computer via a breakout box and custom software provided by R.M. 
Wightman and M.L.A.V. Heien, University of North Carolina, Chapel Hill.  A choridided silver 
wire was used as an Ag/AgCl reference electrode.  The carbon fiber microelectrode was inserted 
100 µm into the dorsolateral caudate-putamen region of the striatum between the prongs of a 
bipolar stimulation electrode (Plastics One, Roanoke, VA), which was separated by a distance of 
200 μm.  The current was then measured at the peak oxidation potential for dopamine (about 
+0.6V versus Ag/AgCl reference electrode).  For the 120-pulse stimulations, DA release was 
measured using stimulation frequencies of 20, 30, 40, 50, and 60Hz at four locations in the 
dorsolateral striatum.  At each location the DA release was measured going from the lowest 
frequency (20 Hz) to the highest frequency (60 Hz) with a 5 minute recovery time between each 
measurement.  Working electrodes were calibrated with dopamine standards of known 
concentration in a flow cell before and after each use.  The average of the pre and post 
calibration measurements was used as the calibration factor. 
For DA efflux studies, single stimulus pulses were applied every five minutes until peak 
dopamine release was consistent over three consecutive measurements.  Once the DA release 
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was consistent, either 50 µM αMPT or 10µM TBZ was added to the aCSF.  The brain slice was 
stimulated every 5 minutes until the DA release peak disappeared.  Next, 20 µM AMPH was 
introduced into the aCSF perfusion solution in addition to the αMPT or TBZ that was already 
present.  AMPH-induced efflux was then measured without the use of electrical stimulation over 
the course of 25 minutes with an update rate of 5 Hz.  This update rate was used in order to limit 
the size of the file.  These data were also background-subtracted and collected at the same scan 
rate and potential limits as the stimulated release data.  For studies using COC, the previous 
procedure for αMPT was followed except that once the DA release peak disappeared, 20µM 
COC was added to the αMPT solution and we continued to apply the single stimulus pulses 
every 5 minutes.  Stimulus pulses were applied for up to 120 minutes in this case in order to 
capture the increase and eventual decrease in stimulated release. 
Data Analysis.  For statistical comparisons, GraphPad Prism (version 4.03) software was used.  
Data are expressed as a mean +/- SEM.  Comparisons were assessed by Student‟s t-test 
(unpaired).  A probability level of 5% (p < 0.05) was considered significant. 
Results 
Striatal DA Release  
It has previously been shown using striatal brain slice preparations that upon single pulse 
electrical stimulation, 12-week old R6/2 mice release significantly less DA than their age-
matched WT controls (Johnson et al., 2006).  To investigate the impact of the HD mutation on 
DA reserve pool mobilization, slices from 12-week old R6/2 and WT mice were subjected to 
120-pulse stimulations at 20, 30, 40, 50, and 60 Hz, and FSCV at carbon fiber microelectrodes 
was used to measure DA release (Fig. 1A).  Cyclic voltammograms obtained at the highest point 
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of stimulated release ([DA]stim) confirm that the analyte detected is dopamine.  Although the DA 
release in WT slices appears to increase as frequency is increased, there was no statistically 
significant difference between stimulation frequencies (Fig. 1B; t-test, p > 0.05).  Conversely, at 
50 and 60 Hz stimulation frequencies, [DA]stim was significantly less in R6/2 slices than in WT 
slices (p < 0.05 at both frequencies).  The average values for [DA]stim at 50 Hz were 1.20 ± 0.33 
µM (R6/2; n = 5 mice) and 2.71 ± 0.47 µM (WT; n = 6 mice).  At 60 Hz, the values were 1.31± 
0.32 µM (R6/2; n = 5 mice) and 3.34 ± 0.76 µM (WT; n = 6 mice). 
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Figure 1.  Striatal DA release, evoked by the application of 120-pulse stimulus pulse trains, is 
impaired in R6/2 brain slices compared with WT brain slices. (a) Representative plots and cyclic 
voltammograms obtained by FSCV at carbon-fiber microelectrodes for R6/2 and WT mice are 
shown. The representative plots where taken using a 60 Hz stimulation frequency. The duration 
of the stimulation is represented by the bar under each plot. The cyclic voltammograms confirm 
the presence of DA. (b) DA release was evoked by 20, 30, 40, 50, and 60 Hz 120-pulse stimulus 
trains. [DA]stim was significantly greater in WT brain slices compared with R6/2 brain slices 
when evoked using 50 and 60 Hz stimulus frequencies (*p < 0.05 at 50 and 60 Hz; n = 5 R6/2 
mice and six WT mice). Although striatal DA release appears to increase with increasing 
frequency in WT slices, differences in release between application frequencies are not significant 
within either genotype (one-way anova). 
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Intracellular DA Levels 
Next, we sought to determine the relative amounts of DA found in pharmacologically 
distinct pools.  Amphetamine- induced DA efflux in brain slices of 6-week and 12-week R6/2 
and WT mice was compared.  Each slice was continuously treated with 10 µM TBZ, which 
blocks the loading of DA into vesicles by inhibiting VMAT (Kung et al. 1994).  RRP dopamine 
was then depleted by applying single-pulse stimulations every five minutes until the stimulated 
release peak disappeared.  At this point, the only dopamine remaining in the terminals is reserve 
pool and free cytosolic DA.  Slices were then exposed to 20 µM AMPH, a competitive dopamine 
transporter (DAT) inhibitor that causes DA efflux from vesicles inside the presynaptic terminal.  
AMPH enters the presynaptic terminal either by lipophilic diffusion through the membrane or by 
passage through the DAT.  AMPH that enters through the DAT causes allosteric translocation of 
the transporter and thereby induces reverse transport of DA from the cytoplasm (Liang & 
Rutledge 1982{Fischer, 1979 #698, Fischer & Cho 1979).  AMPH also displaces vesicular DA 
into the cytoplasm where it can then be released by reverse transport (Chiueh & Moore 1975, 
Jones et al. 1998).  The efflux of DA was measured over the course of 25 minutes.  The 
amplitude of the peak ([DA]AMPH) was used to determine the amount of DA released (Fig. 2A).  
In six-week old R6/2 and WT mice there was not a significant difference in the amount of 
AMPH induced efflux of DA (R6/2, 11.49 ± 2.36 µM, n= 6 mice; WT, 12.41 ±  2.26 µM, n = 7 
mice).  However, by 12 weeks of age, the R6/2 mice showed a significant decrease in AMPH-
induced DA efflux after TBZ treatment (Fig. 2B; p = 0.023; R6/2, 5.41 ± 1.10 µM, n= 7 mice; 
WT, 10.44 ± 1.65 µM, n= 8 mice). 
 
70 
 
 
Figure 2.  AMPH-induced DA efflux after TBZ treatment is impaired in 12-week-old R6/2 mice 
compared with WT mice. (a) Representative data from a 6-week-old WT mouse. The brain slice 
was exposed to 20 μM TBZ while applying single, 4 ms duration stimulus pulses (one pulse 
every 5 min) until DA release disappeared. The slice was then exposed to 20 μM AMPH for 
25 min, and [DA]AMPH was measured. A CV is provided at peak release and confirms the 
presence of DA. Stimulated release plots were collected every 5 min, but are shown every 
10 min for clarity. (b) In 12-week-old R6/2 mice, [DA]AMPH is significantly less than in WT mice 
(*p < 0.05; n = 7 R6/2 mice and 8 WT mice), but at 6-weeks of age there is not a significant 
difference between the two sets of mice (p > 0.05; n = 6 R6/2 and seven WT mice). 
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To measure reserve pool DA more selectively, a separate set of experiments were 
conducted in which slices were exposed to 50 µM αMPT rather than TBZ.  The application of 
αMPT inhibits tyrosine hydroxylase, the rate limiting enzyme in DA synthesis.  A stimulus pulse 
was applied every 5 minutes until the DA peak disappeared, and then AMPH was added to the 
aCSF perfusion solution at a final concentration of 20 μM.  The peak amplitude of the efflux, 
[DA]AMPH  in the presence of aMPT, was measured to quantify the amount of DA stored in 
reserve pool vesicles (Fig. 3).  At 6 weeks of age, there was not a significant difference between 
R6/2 and WT mice (R6/2, 8.17 ± 1.96 µM, n= 5 mice; WT, 5.39 ± 0.88 µM, n= 3 mice).  
Conversely, [DA]AMPH was diminished in slices from 12-week old R6/2 mice compared to age-
matched WT controls (p < 0.05; R6/2, 4.02 ± 0.74 µM, n= 5 mice; WT, 7.75 ± 1.48 µM, n= 4 
mice).  
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Figure 3.  AMPH-induced DA efflux after αMPT treatment is diminished in older R6/2 mice. 
(a) Representative data from a 6-week old WT mouse. Slices were treated with 50 μM αMPT 
until the stimulated DA release peak disappeared. The slice was then exposed to 20 μM AMPH 
for 25 min and [DA]AMPH was measured. The last 20 min of AMPH treatment are shown in this 
particular plot. A CV is provided at peak release and confirms the presence of DA. Stimulated 
release plots collected every 10 min are shown for clarity. (b) AMPH-induced DA efflux was not 
significantly different between 6-week-old R6/2 and WT brain slices (p > 0.05; n = 5 R6/2 and 
three WT mice). [DA]AMPH was significantly decreased in slices from 12-week-old R6/2 mice 
compared with those from age-matched WT control mice (*p < 0.05; n = 5 R6/2 mice and 4 WT 
mice). 
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Mobilization of Reserve Pool DA 
To determine if reserve pool DA is mobilized differently in older R6/2 mice compared to 
respective WT control mice, we used a combination of αMPT and COC, which has also been 
shown to mobilize DA reserve pools (Venton et al., 2006).  DA release, evoked by the 
application of single stimulus pulses, was measured by FSCV in striatal brain slices.  The 
stimulus pulses were applied prior to and throughout the pharmacological treatment of each slice.  
Slices from 12-week old R6/2 and WT mice were treated with 50 µM αMPT.  Once the 
stimulated DA release peak disappeared, slices were treated with 20 µM COC in addition to the 
αMPT.  The WT slices released DA for a longer period of time (90 min) after the addition of 
COC in comparison to R6/2 slices (30 min; Fig. 4A).  The maximum COC-induced DA release 
was not significantly different between the R6/2 and WT mice (Fig. 4B).  Area under the curve 
calculations suggest that the R6/2 slices released less vesicles of DA (41.6% of WT). 
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Figure 4.  Reserve pool vesicles are depleted in 12-week-old R6/2 mice. Slices were treated 
with 50 μM αMPT while applying a 4 ms duration single-pulse electrical stimulus every 5 min. 
Once the stimulated DA release peak disappeared, 20 μM COC was added to the brain slice and 
the application of stimulus pulses continued. Stimulated DA release was measured by FSCV. (a) 
Representative data from R6/2 and WT slices. Reserve pool mobilization by COC resulted in 
measurable stimulated DA release. Stimulated release plots collected immediately after the 
addition of αMPT and the disappearance of the DA release peak have been omitted in this figure 
for clarity. (b) Pooled data from R6/2 and WT mice. Each data point represents the average value 
(± SEM) of [DA]stim obtained from five R6/2 mice and 6 WT mice. The maximum peak 
amplitudes obtained in R6/2 and WT slices were not significantly different. 
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Discussion 
In this study, differences in DA reserve pool storage and mobilization in striatal brain 
slices from R6/2 and WT mice were examined.  In R6/2 slices, electrically-induced release of 
dopamine was non-responsive to increasing stimulation frequencies.  In contrast, release from 
WT slices was significantly greater than that in R6/2 slices at the higher stimulation frequencies.  
Moreover, AMPH-induced DA efflux was diminished in slices from R6/2 mice at 12 weeks of 
age, but not at 6 weeks of age.  However, when efflux currents are normalized against stimulated 
release currents, the data are consistent with an enhancement of cytosolic DA in the striata of 12-
week old R6/2 mice.  Importantly, our data also suggest that after mobilization of the reserve 
pool DA, DA was released from fewer vesicles in slices from 12-week old R6/2 mice compared 
to slices from age-matched WT control mice; thus, fewer reserve pool vesicles are present in the 
R6/2 striatum. 
Previous studies using R6/2 mice have shown that DA release, evoked using a single 
pulse stimulation, is impaired in brain slices from 12-week old R6/2 mice (Johnson et al., 2006).  
This single pulse application causes DA to be released from the RRP which makes up only 1 to 
2% of vesicles in presynaptic terminals (Rizzoli and Betz, 2005).  Similarly, electrically evoked 
release of DA using the 120-pulse stimulation regimen was diminished in R6/2 slices at the 
higher stimulation frequencies (50 and 60Hz) but not at the lower frequencies (20, 30, and 40 
HZ).  Even though peak dopamine levels were observed after the application of about 18 pulses 
at 60 Hz and 15 pulses at 50 Hz, a full 120 pulse regimen was applied in an attempt to reveal 
genotype-related differences.  A difference in [DA] between R6/2 and WT at the end of this 
pulse regimen could potentially suggest a difference in the ability to sustain dopamine release 
during periods of excessive stimulation.  However, there was not a significant difference 
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between the R6/2 and WT mice.  Given that the reserve pool makes up 80 to 90% of vesicular 
DA stores (Neves and Lagnado, 1999; Rizzoli and Betz, 2005), it seems likely that, if these 
stores were mobilized, they would overwhelm and mask the release of RRP DA.  Indeed, the 
average magnitude of DA release, evoked by the application of a 120-pulse train, was on the 
order of 3 to 4 μM from WT slices compared to about 1.5 μM evoked by application of a single 
stimulus pulse (Johnson et al., 2006).  Thus, it is possible that the difference in DA release 
between the R6/2 and WT mice at high stimulation frequencies is driven by the mobilization of 
stored pool vesicles.  According to the standard three pool model, the vesicles in the RRP are 
released first upon mild stimulation in which the axon terminal is depolarized by an action 
potential (Wu and Borst, 1999).  As the RRP becomes depleted, the recycle pool vesicles 
mobilize (Harata et al., 2001; de Lange et al., 2003; Kuromi and Kidokoro, 2003; Richards et al., 
2003). Upon frequent or more intense stimulation, the reserve pool vesicles mobilize (Richards 
et al., 2000; Richards et al., 2003; Heien and Wightman, 2006).  It has been shown that, in 
anesthetized rats, reserve pool DA can be mobilized by stimulating the medial forebrain bundle 
at 5-second intervals using a stimulating  frequency of 30 Hz (Yavich and MacDonald, 2000).    
Phasic DA neuron firing is important for the expression of behavior (Heien and 
Wightman, 2006).  However, it is also important to note that input from cortical glutamate 
afferents may exert control over behavior by driving striatal medium spiny neuron firing (Lape 
and Dani, 2004) and influencing DA release (Kulagina et al., 2001; Avshalumov et al., 2003).  
Tonic DA levels have been proposed to restrain the excitatory effects of glutamate input by 
acting primarily on dopaminergic D1 receptors (Kiyatkin and Rebec, 1999).  The lower 
stimulation frequencies (20 or 30 Hz) are associated more with tonic DA levels in the striatum 
(Hyland et al., 2002; Heien and Wightman, 2006); therefore, because DA release was not 
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significantly different between R6/2 and WT at these frequencies, it appears unlikely that 
differences in tonic dopamine levels play a major role in the propagation of abnormal behaviors 
in these mice.  Conversely, phasic bursts of DA may be associated with upper stimulation 
frequencies (50 and 60 Hz); therefore, it is possible that 12-week old R6/2 mice lack the ability 
to provide the needed phasic dopaminergic input required for normal motor control, thereby 
contributing to the abnormal behavioral phenotype.   
The DA reserve pools were examined using various pharmacological agents. Treating the 
brain slices with TBZ coupled with electrical stimulation will deplete the releasable vesicles.  
Upon the addition of AMPH intracellular and vesicular DA will exit the terminals by reverse 
transport through the DAT into the extracellular space (Sulzer et al., 1995; Floor and Meng, 
1996; Jones et al., 1998; Schwartz et al., 2005; Watanabe et al., 2005).  The diminished DA 
efflux in 12-week old R6/2 mice indicates that DA, not released by stimulation with a single 
electrical pulse, becomes progressively depleted between 6 and 12 weeks of age.  This DA is 
made up of reserve pool DA and free cytosolic DA.  Similar results were obtained when reserve 
pool DA was selectively isolated by treatment of slices with αMPT, which, when combined with 
electrical stimulation, depletes releasable DA stores and free cytosolic DA.  R6/2 mice typically 
develop the overt motor phenotype at 9 to 11 weeks of age; thus, the timescale of reserve pool 
depletion is consistent with the occurrence of motor symptoms.   
A goal of this work was also to determine if cytosolic DA levels differ between R6/2 and 
WT mice.  Presumably, the relative levels of cytosolic DA can be obtained by subtraction of 
[DA]AMPH obtained from αMPT-treated slices, from [DA]AMPH obtained from TBZ-treated slices.  
However, because the errors associated with this operation are additive, the calculated 
differences were not significant between R6/2 and WT.  For this reason, we normalized efflux 
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current values against respective pre-drug stimulated release current values individually for each 
curve, which eliminated potential errors associated with electrode calibration and also corrected 
DA efflux for differences in stimulated DA release.  No significant differences in normalized 
efflux current were present following treatment of slices from 6-week old mice with either TBZ 
or αMPT; however, the average normalized efflux current in αMPT-treated slices from 12-week 
old R6/2 mice was diminished compared to WT, while no difference was noted following TBZ 
pre-treatment.  When combined with the application of single stimulus pulses, spaced 5 minutes 
apart, TBZ pre-treatment should result in the depletion of all DA except what is present in the 
cytosol and the DA reserve pool, while αMPT pre-treatment should result in the removal of all 
cytoplasmic DA except for that in the reserve pool.  Therefore, our interpretation is that, at 12 
weeks of age, an enhanced level of cytosolic DA is present in the R6/2 striatum compared to WT 
controls.  This interpretation would be consistent with previous findings that vesicle loading by 
the vesicular monoamine transporter (VMAT) is impaired in adrenal chromaffin cells from R6/2 
mice (Johnson et al., 2007), a phenomenon that may very well apply to vesicle loading in the 
striatum.  This enhanced level of DA may also result in further intracellular damage, given the 
chemically reactive nature of DA.       
More commonly known as a dopamine uptake inhibitor, COC has a similar affinity for 
DAT in R6/2 mice as compared to WT mice (Johnson et al, 2006).  Thus, the differences seen 
after treating R6/2 and WT slices with COC following pre-treatment with αMPT most likely 
arise from differences in reserve pools release, not differences in uptake. Because the peak DA 
levels evoked by single pulse electrical stimulation are the same in R6/2 and WT control slices 
under these conditions, it is likely that R6/2 mice can mobilize reserve pool vesicles normally, 
and that the vesicles contain the same number of DA molecules.  These results also imply that 
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there are similar densities of DA-releasing presynaptic terminals in the R6/2 and WT striata.  
However, the DA release lasted roughly three times as long in slices from WT mice compared to 
slices from R6/2 mice, suggesting that R6/2 mice suffer from a depletion of the number of DA 
reserve pool vesicles (approximately 41.6% of WT, according to area under the curve 
calculations).  Although the normal intracellular functions of the endogenous Htt protein are not 
fully understood, recent studies have shown that the expanded CAG repeat, along with 
promoting the formation of aggregates in neurons of both HD model mice and people who have 
HD (Cooper et al., 1998; Hazeki et al., 1999; Meade et al., 2002), can also cause impairments in 
vesicular transport (Edwardson et al., 2003; Morton et al., 2001; Li et al., 2003).  It is therefore 
possible that the R6/2 mice have fewer reserve pool vesicles because they are unable to transport 
vesicles or maintain vesicles in the reserve pool as well as WT mice.          
Collectively, our data suggest that a progressive loss of DA reserve pool vesicles may 
contribute to the progressive behavioral phenotype of R6/2 mice.  Moreover, our data are 
consistent with the concept that vesicle loading is impaired, resulting in enhanced intracellular 
DA levels.  These findings may help guide the development of therapeutic interventions to treat 
chorea and other motor syndromes associated with HD.  Additionally, future research efforts 
may be aimed at resolving the cellular mechanisms that are responsible for the depletion of the 
DA reserve pool. 
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Chapter 4: MsrA 
The study of oxidative stress and how it affects the DA system including the reserve pool 
veiscles and the D2 autoreceptors was conducted.  The results are published in the following two 
papers. 
A. Quantification of Reserve Pool DA in MsrA Null Mice 
Methionine sulfoxide reductase A knockout (MsrA
-/-
) mice, which serve as a potential 
model for neurodegeneration, suffer from increased oxidative stress and have previously been 
found to have chronically elevated brain dopamine content levels relative to control mice.  
Additionally, these high levels parallel increased presynaptic dopamine release.  In this work, 
fast-scan cyclic voltammetry at carbon-fiber microelectrodes was used to quantify striatal reserve 
pool dopamine in knockout mice and wild-type control mice.  Reserve pool dopamine efflux, 
induced by amphetamine, was measured in brain slices from knockout and wild type mice in the 
presence of α-methyl-p-tyrosine, a dopamine synthesis inhibitor.  Additionally, the stimulated 
release of reserve pool dopamine, mobilized by cocaine, was measured.  Both efflux and 
stimulated release measurements were enhanced in slices from knockout mice, suggesting that 
these mice have greater reserve pool dopamine stores than wild-type and that these stores are 
effectively mobilized.  Moreover, dopamine transporter labeling data indicate that the difference 
in measured dopamine efflux was likely not caused by altered dopamine transporter protein 
expression.  Additionally, slices from MsrA
-/- 
and wild-type mice were equally responsive to 
increasing extracellular calcium concentrations, suggesting that potential differences in either 
calcium entry or intracellular calcium handling are not responsible for increased reserve pool 
dopamine release.  Collectively, these results demonstrate that MsrA
-/-
 knockout mice maintain a 
larger dopamine reserve pool than wild-type control mice, and that this pool is readily mobilized. 
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Introduction 
The abnormal regulation of dopamine (DA) has been associated with multiple 
neurodegenerative disease states (Bird and Iversen, 1974, Morgan et al., 1987), yet the role of 
DA reserve pool storage and mobilization in the pathophysiology of these conditions is now just 
being revealed.  Many of these conditions, such as Parkinson‟s disease, Huntington‟s disease, 
and Lou Gehrig‟s disease, have been associated with the increased production or reactive oxygen 
species, thereby enhancing the degree of cell oxidative stress in the brain (Patten et al., 2010, 
Cohen, 1983, Perez-Severiano et al., 2004).    
Interestingly, elevated DA levels have also been associated with enhanced oxidative stress 
(Oien et al., 2008b).  Indeed, one model of oxidative stress, methionine sulfoxide reductase A 
knockout (MsrA
-/-
) mice, have been reported to have chronically high brain DA levels (Oien et 
al., 2008b).  These mice lack the antioxidant enzyme MsrA, which is part of the Msr system.  
Methionine sulfoxide posttranslational modifications can be reversed by the Msr system, which 
consists of MsrA (reduces S methionine sulfoxide enantiomer) and MsrB (reduces R methionine 
sulfoxide enantiomer) (Moskovitz, 2005).  The MsrA
-/-
 mouse is hypersensitive to oxidative 
stress, accumulates higher levels of carbonylated protein, and expresses brain pathologies 
associated with neurodegenerative diseases (Moskovitz et al., 2001, Pal et al., 2007).  Recent 
studies have shown that these mice have abnormally high DA levels in the brain at the ages of 6 
and 12 months, compared to wild type (WT) control mice. Additionally, these high levels 
parallel an increased presynaptic DA release when stimulated in vitro without drug treatments. 
A possible mechanism for an increase in stimulated DA release in MsrA
-\-
 mice involves the 
mobilization of reserve pool DA.  In general, DA-containing vesicles are believed to be 
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separated into three pools:  the readily releasable pool (RRP), the recycling pool, and the reserve 
pool (Neves and Lagnado, 1999, Rizzoli and Betz, 2005).  The RRP undergoes exocytosis upon 
mild stimulation and is replenished by the mobilization of the recycling pool vesicles.  The 
reserve pool, mobilized upon prolonged periods of synaptic activity (Neves and Lagnado, 1999), 
is the largest pool consisting of 80-90% of the total vesicles (Rizzoli and Betz, 2005).  
Pharmacological manipulations, using a combination of alpha-methyl-p-tyrosine (aMPT) and 
either cocaine (COC) or amphetamine (AMPH) (Venton et al., 2006, Ortiz et al., 2010), have 
been used to quantitatively measure reserve pool dopamine. 
Other factors, such as calcium transport, may also influence the amplitude of stimulated 
dopamine release plots.  Transient increases in intracellular calcium concentration trigger 
vesicular exocytosis (Nachshen and Sanchez-Armass, 1987, Kume-Kick and Rice, 1998) as well 
as the movement of RRP and reserve pool vesicles (Rose et al., 2002).  Moreover, the increase in 
oxidative stress may result in calcium dysregulation.  For example, the activity of calmodulin, a 
calcium regulatory protein that activates the plasma membrane calcium ATPase (PMCA), 
diminishes due to oxidative post-translational modifications as tissues age (Michaelis et al., 
1996).  The oxidation of specific methionines in calmodulin results in about a 50% reduction of 
PMCA activation (Bartlett et al., 2003), thereby impairing the ability of cells to clear calcium 
from the cell (Palacios et al., 2004).  Oxidized calmodulin can accumulate in brain tissues as a 
result of low antioxidant levels and it is speculated that oxidation of methionines on calmodulin 
may be acting as a molecular switch in calcium regulation, oxidative stress, and DA release 
(Chen et al., 2001, Bigelow and Squier, 2005).   
To investigate possible mechanisms underlying elevated DA content and release found in 
MsrA
-/-
 mice, fast-scan cyclic voltammetry (FSCV) at carbon-fiber microelectrodes was used to 
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measure the mobilization and efflux of reserve pool DA in striatal brain slices from MsrA
-/-
 mice 
and WT control mice (Oien et al., 2008b).  We hypothesized that the DA reserve pool is 
enhanced in MsrA
-/-
 mice compared to WT control mice.  In order to measure reserve pool DA, 
slices were pre-treated with αMPT and then treated with either AMPH, to measure the efflux of 
reserve pool DA, or with COC, to measure the stimulated release of mobilized DA reserve pool 
vesicles.  Collectively, our results suggest that reserve pool DA is more abundant in the MsrA
-/-
 
striatum and that the number of vesicles is greater compared to WT controls.     
Experimental Procedures 
Animals.  The MsrA
-/- 
and WT control mice have been described previously (Moskovitz et 
al., 2001).  All mice used in these experiments were fed ad libitum, housed with 12 h of light per 
day, and caged individually.  All procedures and conditions of live mice, including euthanasia, 
were approved by the University of Kansas Institutional Animal Care and Use Committee.  
Every effort was made to minimize the number of animals used and animal suffering.  
Brain Slice Preparation. Brain slices of 12-month-old MsrA
-/- 
mice and age-matched WT 
mice were prepared as previously described (Johnson et al., 2006). Mice were anesthetized by 
isoflurane inhalation and then decapitated.  The brain was immediately removed and placed in 
ice cold artificial cerebrospinal fluid (aCSF) consisting of (mM): NaCl 126, KCl 2.5, NaH2PO4 
1.2, CaCl2 2.4, MgCl2 1.2, NaHCO3 25, HEPES 20, and D-Glucose 11.  The pH of the aCSF was 
adjusted to 7.4.  The cerebellum was removed from the brain using a razor blade and the brain 
was then mounted on an aluminum block.  A vibratome slicer (Leica, Wetzlar, Germany) was 
used to make 300 µm thick coronal slices.  Each brain slice was equilibrated in the superfusion 
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chamber which was maintained at 34°C, through which aCSF flowed at a continuous rate of 2 
mL/min, prior to obtaining measurements. 
DA Release in Brain Slices. Carbon-fiber microelectrodes were fabricated using a single 7 
μm diameter carbon-fiber (Goodfellow Cambridge Ltd, Huntingdon, U.K.) that was aspirated 
through a glass capillary tube (1.2 mm outer diameter, 0.68 mm inner diameter, 20 mm long, A-
M Systems, Inc. Carlsborg, WA), and was pulled using a heated coil puller (Narishige 
International USA, Inc., East Meadow, NY) (Kraft et al., 2009). The carbon-fiber was trimmed 
to about 25 µM and further insulated using with epoxy resin (EPON resin 815C, EPIKURE 3234 
curing agent, Miller-Stephenson, Danbury, CT, USA), and then cured at 100C for 1 h.  The 
electrodes were backfilled with 0.5 M potassium acetate to provide an electrical connection 
between the carbon fiber and an inserted silver wire. 
A triangular waveform was applied to the carbon-fiber electrode starting at -0.4 V, increasing 
to +1.0 V, and then scanning back down to -0.4 V.  For stimulated release measurements, a scan 
rate of 300 V/s and an update rate of 60 cyclic voltammograms (CVs) per second were used.  For 
measurements of AMPH-induced DA efflux, an update rate of 5 CVs was used to limit the 
memory space occupied by the file.  A headstage amplifier (UNC Chemistry Department 
Electronics Design Facility, Chapel Hill, NC) was interfaced with a computer via a breakout box 
and custom software provided by R.M. Wightman and M.L.A.V. Heien (University of North 
Carolina, Chapel Hill).  A Ag/AgCl reference electrode consisted of a chorided silver wire.  The 
carbon fiber microelectrode was inserted 100 µm into the dorsolateral caudate-putamen region of 
the striatum between the prongs of a bipolar stimulation electrode (Plastics One, Roanoke, VA), 
which was separated by a distance of 200 μm.  A single pulse at 60 Hz was applied to the brain 
slice and the current was then measured at the peak oxidation potential for DA (about +0.6 V 
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versus Ag/AgCl reference electrode).  Working electrodes were calibrated with DA standards of 
known concentration in a flow cell before and after each use.  The average of pre- and post-
calibration measurements was used as the calibration factor.  Drugs were introduced into the 
brain slice superfusion chamber by opening a three-way valve that allowed the desired solution 
to flow by gravity feed.  
For AMPH-induced DA efflux experiments, brain slices were stimulated with single 
electrical stimulus pulses until the magnitude of evoked DA release was consistent between 
measurements.  Brain slices were then treated with 50 µM aMPT.  During this treatment, 
stimulated DA release was measured every 5 min.  Once DA release diminished, 20 µM AMPH 
was added to the aCSF/aMPT solution and a 25 min duration file was collected.   
To measure electrically evoked DA release from mobilized reserve pool vesicles, the same 
procedure for pre-treatment with aMPT was used.  However, slices were treated with 20 µM 
COC after stimulated release was diminished.  During this treatment, electrically-evoked release 
was measured every 5 minutes. 
Sensitivity of DA release to extracellular calcium. To measure changes in the sensitivity to 
calcium in MsrA
-/- 
mice DA release evoked by a single electrical stimulus pulse was first 
measured in slices with aCSF that contained 2.4 mM calcium.  Next, aCSF containing 0 mM 
calcium was introduced into the superfusion chamber.  Once DA release disappeared, brain 
slices were cumulatively treated with aCSF containing 0.6, 1.2, 1.8, and 2.4 mM calcium.  Slices 
were treated with each concentration for 15 min, with files collected every five 5 min using a 
single pulse stimulation.  Values obtained at the 15 min point were used in Fig. 4. 
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Immunoblotting. MsrA
-/-
 and WT brains were dissected from post-mortem mice.  Each 
striatal lysate was placed in a glass tube and homogenized with Teflon in 50 mM HEPES buffer 
pH 7.4 plus protease inhibitors (Roche) at 4°C. Homogenized extract was centrifuged for 20 min 
to separate the membrane fraction.  Buffer containing 50 mM HEPES, 0.62% CHAPS, and 150 
mM NaCl was added to each membrane fraction and agitated for 30 min.  Each fraction was 
centrifuged for 20 min.  Protein concentration of the supernatant was determined by BCA 
Protein Assay Kit (Pierce).  Equal protein amounts (20 µg) of each soluble membrane fraction 
was loaded into a HEPES 4-20% Protein Gel (Pierce, Pittsburg, PA) and submitted to 
electrophoresis.  Proteins were transferred to a nitrocellulose membrane and blocked overnight in 
5% dry milk in buffer.  Protein was detected using rabbit anti-DAT antibody (1:1000; Chemicon, 
Billerica, MA).  Primary antibodies were detected by horseradish peroxide-conjugated goat-anti-
rabbit secondary antibodies (1:2000; Bio-Rad, Hercules, CA).  Protein bands were visualized by 
chemiluminescent substrate and exposure to autoradiography film.  Densitometry analysis was 
done using ImageJ software (publicly available software obtained from the National Institutes of 
Health website). 
Statistical Analyses.  Data were analyzed by ANOVA or students t-test using GraphPad 
Prism 4.03 (GraphPad Software, Inc., La Jolla, CA).  All numerical values are represented as 
mean ± SEM.  A p value of 0.05 or less was considered significant.   
Results 
Reserve Pool DA Levels 
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It has been previously demonstrated that in MsrA
-/-
 mice stimulated DA release, evoked 
by a single-pulse electrical stimulation, is significantly higher than that of WT controls (Oien et 
al., 2008b).  To determine if reserve pool DA is similarly more abundant in MsrA
-/-
 mice, striatal 
brain slices were subjected to treatment with aMPT and AMPH-induced efflux was measured.  
Each slice was treated with 50 µM aMPT to inhibit tyrosine hydroxylase, the rate limiting 
enzyme in DA synthesis.  A stimulus pulse was then applied to the slice every 5 min until DA 
release was diminished.  At this point, DA remaining in terminals consisted only of reserve pool 
DA.  The slices were then treated with 20 µM AMPH, a competitive DAT inhibitor that induces 
the quantitative efflux of cytosolic and vesicular DA.  AMPH enters the pre-synaptic terminals in 
one of two ways: either by lipophilic diffusion through membranes or by passage through DAT 
protein molecules (Fischer and Cho, 1979, Liang and Rutledge, 1982).  AMPH also displaces 
vesicular DA into the cytoplasm where it can be released by reverse transport caused when 
AMPH enters through the DAT causing allosteric translocation of the transporters (Chiueh and 
Moore, 1975, Jones et al., 1998). The AMPH induced efflux of DA was measured over the 
course of 25 min and the amplitude of the DA peak ([DA]AMPH) was used to determine the 
amount of DA released (Fig.1a).  A CV shown at the peak current on this efflux curve indicates 
that the species released by AMPH treatment is DA.  In MsrA
-/-
 mice, AMPH-induced DA efflux 
was significantly greater than that observed in WT control mice, indicating that the striatal DA 
reserve pool is enhanced in MsrA
-/-
 mice (Fig. 1b; p = 0.022; MsrA
-/-
, 7.02 ± 1.42 µM, n = 5 
mice; WT, 5.63 ± 0.33 µM, n = 4 mice).   
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Figure 1.  AMPH induced DA efflux is increased in MsrA
-/-
 mice compared to WT mice.  (A) 
Representative data in which a brain slice from a WT mouse was treated with 50 μM aMPT while single 
stimulus pulses were applied every 5 min until DA release was diminished.  The slice was then treated 
with 20 μM AMPH for 25 min, and [DA]AMPH was measured. A CV is provided from the time of peak 
release, and confirms the release of DA. (B) In MsrA
-/-
 mice, [DA]AMPH is significantly higher in MsrA
-/-
 
slices than in WT slices ( *p < 0.05; MsrA
-/-
, 7.02 ± 1.42 µM, n = 5 mice; WT, 5.63 ± 0.33 µM, n = 4).   
 
 
 
 
94 
 
Mobilization of Reserve Pool DA 
To identify differences in the exocytotic release of mobilized DA reserve pool vesicles, 
DA release, electrically evoked in striatal brain slices from MsrA
-/-
 and WT mice control mice, 
was measured with FSCV (Fig. 2a).  Once DA release peak amplitude was the same between 
separate stimulations in the absence of drug, aMPT was added to the perfusate at a final 
concentration of 50 μM in order to stop DA synthesis.  After DA release was diminished, COC 
was added to the aMPT/aCSF solution at a final concentration of 20 μM.  COC has previously 
been shown to mobilize reserve pool DA (Venton et al., 2006).  DA release was electrically 
evoked by the application of locally applied single stimulus pulses every 5 min throughout the 
entire process.  The addition of COC caused stimulated DA release to grow in both MsrA
-\-
 and 
WT control slices.  Although COC treatment caused DA release to increase to similar levels in 
MsrA
-/-
 and WT control slices, DA release reappeared for a longer amount of time in slices from 
MsrA
-/-
 mice (~180 min) compared to slices from WT mice (~80 min)(Fig. 2b).  The area under 
the curve generated using slices from WT mice was 40% of that generated using slices from 
MsrA
-/-
 mice.     
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Figure 2.  More reserve pool DA is mobilized in slices from MsrA
-/-
 mice compared to those from 
WT mice.  Brain slices from MsrA
-/- 
and WT mice were exposed to 50 μM aMPT while single stimulus 
pulses were applied every 5 min.  Once DA release disappeared, 20 μM COC was added to the slice.  The 
application of stimulus pulses was continued during this time.  (A) Representative data from MsrA
-/- 
and 
WT slices. The addition of COC after pretreatment with aMPT resulted in an increase in stimulated DA 
release.  Stimulated release plots taken immediately after the addition of aMPT have been omitted for 
clarity. (B) Pooled data from MsrA
-/-
 and WT mice after the addition of COC. Each data point represents 
the average value (± SEM) of [DA]stim obtained from 5 MsrA
-/-
 mice and 6 WT mice. 
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DAT Protein Levels 
 
The DAT is a transmembrane protein that moves DA from the synaptic cleft into the presynaptic 
neuron.  In membrane fractions of MsrA
-/-
 and WT mice, no difference in DAT protein levels 
was detected (Fig. 3; p = 0.65; MsrA
-/-
, 100.0 ± 19.8 %, n = 3 mice; WT, 115.6 ± 4.1 %, n = 3 
mice).  These data are consistent with a previous report that showed synaptic DA clearance was 
similar between MsrA
-/-
 and WT mice (Oien et al., 2008).  
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Figure 3.  DAT protein levels are unchanged in MsrA
-/-
 mice.  MsrA
-/-
 and WT cerebral membrane 
fractions were solubilized and equal amounts of protein were separated by gel electrophoresis.  (A) 
Protein bands detected by anti-DAT antibodies indicate similar amounts of the protein at about 70 kDa.  
(B) Densitometry values of protein bands are shown as an average density from MsrA
-/- 
(black) and WT 
(white) bands (p = 0.69; n = 3 MsrA
-/-
 and 3 WT mice).   
98 
 
Extracellular Calcium Sensitivity 
Vesicular DA exocytosis in the striatum is directly dependent on available extracellular calcium, 
which enters pre-synaptic terminals by voltage-gated calcium channels during membrane 
depolarization (Heuser and Reese, 1973; Cremona and De Camilli, 1997).   In order to evaluate 
whether the calcium dependency of release was altered in MsrA
-/-
 mice, brain slices were treated 
with various concentrations of extracellular calcium and stimulated DA release was measured 
(Fig. 4).  A two-way ANOVA did not reveal an overall genotype effect on DA release 
throughout the entire range of extracellular calcium concentrations (Fig. 4; p = 0.51; F1,21 = 0.48; 
MsrA
-/-
, n = 4 mice; WT, n = 6 mice).   
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Figure 4.  Calcium-dependent release was unchanged in 12-month-old MsrA
-/-
 mice compared to 
age-matched WT mice.  Brain slices were treated with 0, 0.6, 1.8, and 2.4 mM concentrations of 
extracellular calcium and electrically stimulated DA release was measured for 15 min at each 
concentration.  DA release was normalized to maximum DA release within each data set.  At 0 mM 
calcium no DA release was detected.  Two-way ANOVA did not reveal an overall genotype effect on DA 
release throughout the entire range of extracellular calcium concentrations (Fig. 4; p = 0.51; F1,21 = 0.48; 
MsrA
-/-
, n = 4 mice; WT, n = 6 mice).   
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Discussion 
Previous studies using MsrA
-/-
 mice have shown that DA release evoked using a single-pulse 
stimulation is increased (Oien et al., 2008b).  In the present study, differences in DA reserve pool 
storage and mobilization in striatal brain slices from MsrA
-/-
 mice and WT control mice were 
examined.  AMPH-induced DA efflux, following pre-treatment with αMPT, was increased in 
striatal brain slices from MsrA
-/-
 mice compared to those of WT littermates.  Moreover, MsrA
-/-
 
slices showed an enhanced degree of COC-induced mobilization of DA reserve pool vesicles 
compared to WT.  Furthermore, slices from MsrA
-/-
 mice and WT control mice were equally 
sensitive to changes in extracellular calcium concentration. 
Initial experiments were aimed at determining if alterations in either DAT or calcium 
regulation preferentially enhanced DA release in MsrA
-/-
 mice.  Our previous work has shown 
that the efficiency of DA reuptake by DAT is similar in MsrA
-/- 
and WT mice (Oien et al., 
2008b).  Furthermore, here we show that DAT protein levels are similar in MsrA
-/- 
and WT mice.  
This result further supports the concept that DAT function and protein levels are not altered in 
the absence of MsrA.  Therefore, we expect that COC and AMPH effects on the DAT would be 
similar in both mice genotypes.  
The exocytotic release of DA during synaptic transmission is mediated by calcium-dependent 
fusion with the active zone (Heuser and Reese, 1973; Cremona and De Camilli, 1997; Kavalali, 
2006).  Thus, the ability of extracellular calcium to enter through N- and P/Q-type voltage-gated 
calcium channels (VGCCs) located at the active zone exerts a strong influence over 
neurotransmitter release (Fox and Currie, 1997).  We observed no difference in electrically 
evoked DA release between MsrA
-/-
 and WT slices when extracellular calcium concentrations 
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were increased, suggesting that the VGCCs were functioning similarly.  However, it is possible 
that other calcium handing mechanisms are altered in MsrA
-/-
 mice, and that these alterations 
may somehow influence the ability of terminals to release DA, especially since intracellular 
calcium can influence the movement of vesicular DA between RRP and reserve pools (Rose et 
al., 2002).   
One potential mechanism that could increase intracellular calcium levels is the oxidative 
inactivation of calcium regulatory proteins.  In particular, methionine oxidation of calcium 
regulatory proteins, such as calmodulin (Michaelis et al., 1996) and calcium/calmodulin kinase II 
(Erickson et al., 2008), increases with age and is also increased in selenium deficient MsrA
-/-
 
mice compared to WT control mice (Moskovitz, 2007).  An elevation in intracellular calcium 
associated with the lack of calcium chelating ability may be associated with increased reserve 
pool DA in MsrA
-/- 
mice because calcium accelerates the mobilization of vesicles from the 
reserve pool stores (Kline et al., 2002).   
To assess the content and mobilization of reserve pool DA in MsrA
-/-
 and WT control mice, 
selected pharmacological agents were used.  Treating brain slices with aMPT while electrically 
stimulating the brain slice depletes DA in RRP vesicles.  Under these conditions, DA in the 
extracellular space will be packaged and also released, leaving only DA in reserve pool vesicles 
(Ortiz et al., 2010).  Upon the addition of AMPH, DA in the reverse pool vesicles is released by 
reverse transport through the DAT and we are able to measure the resulting efflux.  We found 
that, compared with WT littermate controls, AMPH-induced DA efflux is greater in MsrA
-/-
 
slices compared to WT slices, indicating that MsrA
-/-
 mice have an increased supply of reserve 
pool dopamine.  This increase parallels both the enhancement of stimulated DA release and the 
increase in striatal DA content found previously in MsrA
-/-
 mice (Oien et al., 2008b).  Because 
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equal levels of the DAT protein are found in MsrA
-/-
 and WT mice, and DA uptake in the 
absence of pharmacological treatments appears to be similar between the two strains, it is 
unlikely that the enhancement of DA efflux found in the MsrA
-/-
 striatum is the result of 
alterations in DAT expression or function.  Thus, our results suggest that the overall amount of 
reserve pool DA is increased in the MrsA
-/-
 striatum.      
When DA reserve pool vesicles are mobilized by the application of COC, peak DA release 
evoked by single-pulse stimulation was the same between the MsrA
-/- 
and WT mice, implying 
that there are the same number of DA molecules contained in each mobilized reserve pool 
vesicle.  Because the peak dopamine release is attained earlier in WT mice than in MsrA
-/-
 mice, 
impaired mobilization of reserve pool vesicles in the MsrA
-/-
 cannot be ruled out.  Area under the 
curve calculations suggest that the WT striatum possesses 40% the number of DA reserve pool 
vesicles found in the MsrA
-/-
 striatum.  This figure is in close agreement with the amount of DA 
released by electrical stimulation in the WT striatum (37% of MsrA
-/-
; Oien et al., 2008b).  Thus, 
a greater overall number of vesicles, albeit a similar proportion in relation to the reserve pool, are 
mobilized into the RRP in MsrA
-/-
 mice than in WT mice.  These vesicles then undergo 
exocytosis upon the application of a mild electrical stimulus pulse, which is intended to simulate 
the occurrence of a natural action potential.  We speculate that this increase in the number of 
reserve pool vesicles enhances the magnitude of naturally occurring DA release events in MsrA
-/-
 
mice.   
The mechanism of the chronically increased DA levels in MsrA
-/-
 mice is still unknown.  The 
abnormally high brain DA in MsrA
-/-
 mice can be alleviated by caloric restriction (Oien et al., 
2010), suggesting that metabolism and oxidative stress related mechanisms are involved in this 
phenomenon.  Previous studies suggest an increase of the tyrosine hydroxylase activating protein 
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14-3-3zeta mRNA (Oien et al., 2008a) and protein (Oien et al., 2008b) may be associated with 
the increased levels of DA by enhanced DA synthesis.  In addition, we have recently reported 
that methionine oxidation of the dopamine D2 receptor may participate in DA signaling in MsrA
-
/-
 mice (Oien et al., 2010), which may include the presynaptic D2 autoreceptor isoform.  Another 
possible explanation for this abnormal DA regulation is increased methionine sulfoxide levels in 
alpha-synuclein that may interfere with its interaction with DA (Oien and Moskovitz, 2008, Oien 
et al., 2009, Outeiro et al., 2009).  This theory is further supported by defective mobilization of 
DA from reserve pools in alpha-synuclein knockout mice and A30P mutated alpha-synuclein 
transgenic mice (Yavich et al., 2004, Yavich et al., 2005).  In any case, it is apparent that 
dopaminergic neurons store this excess DA in reserve pool vesicles. 
In summary, this work has identified an intracellular mechanism by which MsrA
-/-
 mice store 
excess DA.  To our knowledge, this is the first published study in which reserve pool DA levels 
have been directly measured in mice that are genetically altered to have increased oxidative 
stress.  Moreover, this study offers a potential mechanism by which neurons cope with the 
excessive production of DA, and also provides a strategy for the study other DA-related 
pathologies.    
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Chapter 5: Conclusion 
The main focus of my research has been on the effects of neurodegentation and oxidative 
stress on the release of DA.  In my studies of HD we have shown that the release of DA 
decreases in an age dependent manner in transgenic R6/1 and R6/2 mice (Ortiz et al., 2010, 
2011a).  This inhibition was not present in the chemically-induced 3NP treated rat model (Ortiz 
et al., submitted).  Another difference between the two types of models was found when the 
number of DA reserve pool vesicles was measured.  Using αMPT and AMPH to measure DA 
efflux the amount of DA release was decreased in 12 week old R6/2 mice and increased in 3NP-
treated rats (Ortiz et al., 2010).  Using a combination of αMPT and COC the DA reserve pool in 
R6/2 mice was once again measured and showed that the amount of DA in each vesicle was the 
same but the number of vesicles in the reserve pool was significantly decreased in the R6/2 mice 
(Ortiz et al., 2010). This has led us to believe that the chemically induced model may not be a 
good model of HD especially when compared to the genetically induced models. 
 Future studies for these projects include examining other chemically induced models of 
HD to determine if the discrepancies we found using the 3NP model are present in other 
chemically induced models.  This would allow us to find a more reliable HD chemical model to 
use.  The transgenic mouse models used were both from the R6 mouse germ line so it would be 
important to examine other mouse models such as the YAC model.  Another aspect of this 
project that should be further studied is the reserve pool vesicles.  By using fluorescence imaging 
it would be possible to quantify the number and location of reserve pool vesicles.   
 Neurodegenerative diseases and aging are both associated with oxidative stress and by 
studying the underlying mechanisms allows for potential future pharmaceutical approaches.  
Using the MsrA knockmouse we were able to study oxidative stress and the effects that it has on 
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DA release.  The reserve pool DA was measured using αMPT and AMPH and also using αMPT 
and COC.  We found that the reserve pool DA levels were increased in the MsrA
-/-
 and that there 
was an increase in the number of vesicles present and each vesicle had the same amount of DA 
when compared to age matched wild type mice (Ortiz et al., 2011b).  The DA release was also 
measured in brain slices in the presence of increasing calcium levels.  There was no difference in 
DA release between the various calcium levels suggesting the calcium regulatory proteins, such 
as calmodulin and calcium/calmodulin kinase II in MsrA
-/-
, are functioning properly (Oien et al., 
2010).  These results also suggest that DA release is not increasing or decreasing due to calcium 
levels as calcium levels also help to regulate vesicular mobilization and release.  The increase of 
DA was thought to be due to an increase in DA synthesis which is due to a lack of autoreceptor 
signaling which is modulated by D2 receptors. The study of the D2 receptors in MsrA mice was 
done using D2 agonists and antagnosits, quinpirole and sulpiride.  The MsrA
-/-
 were less 
responsive to both quinpirole and sulpiride indicating poor D2 signaling (Oien et al., 2010).   
 Future studies for the MsrA project include looking further at the D2 autoreceptor as the 
current hypothesis is that the increase in DA synthesis found in these mice is due to poor D2 
signaling.  One possible way to further study the D2 autoreceptor is to purify the D2 protein and 
use mass spectrometry to look for possible changes in the oxidation of methionine residues.  
After the location of oxidation is found then these results can be compared to the oxidation that 
occurs in people with neurodegenerative disease. 
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Appendix 
 
Dopamine D2 Function is Compromised in the Brain of MsrA
-/-
 Mice 
Work described in this appendix is based in part on work accomplished by Andrea Ortiz in 
collaboration with Dr. Derek Oien (then student of Prof. Jackob Moscovitz) and others.  This 
work is published under the following reference: 
 
Oien DB, Ortiz AN, Rittel AG, Dobrowsky RT, Johnson MA, Levant B, Fowler SC, Moskovitz J 
(Dopamine D2 Receptor Function is Compromised in the Brain of the Methionine Sulfoxide 
Reductase A Knockout Mouse. J Neurochem 114(1):51-61.2010). 
 
Previous research suggests that brain oxidative stress and altered rodent locomotor 
behavior are linked. We observed bio-behavioral changes in methionine sulfoxide reductase A 
knockout mice associated with abnormal dopamine signaling. Compromised ability of these 
knockout mice to reduce methionine sulfoxide enhances accumulation of sulfoxides in proteins. 
We examined the dopamine D2-receptor function and expression, which has an atypical 
arrangement and quantity of methionine residues. Indeed, protein expression levels of dopamine 
D2-receptor were higher in knockout mice compared with wild-type. However, the binding of 
dopamine D2-receptor agonist was compromised in the same fractions of knockout mice. 
Coupling efficiency of dopamine D2-receptors to G-proteins was also significantly reduced in 
knockout mice, supporting the compromised agonist binding. Furthermore, pre-synaptic 
dopamine release in knockout striatal sections was less responsive than control sections to 
dopamine D2-receptor ligands. Behaviorally, the locomotor activity of knockout mice was less 
responsive to the inhibitory effect of quinpirole than wild-type mice. Involvement of specific 
methionine residue oxidation in the dopamine D2-receptor third intracellular loop is suggested by 
in vitro studies. We conclude that ablation of methionine sulfoxide reductase can affect 
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dopamine signaling through altering dopamine D2-receptor physiology and may be related to 
symptoms associated with neurological disorders and diseases. 
 
 
Introduction 
Post-translational modifications resulting from reactive oxygen species can alter the 
functions of many proteins. While most protein modifications by reactive oxygen species are 
irreversible, methionine sulfoxide (MetO) modifications can be reversed by the methionine 
sulfoxide reductase (Msr) system, which consists of MsrA (reduces S-MetO) and MsrB (reduces 
R-MetO) (Moskovitz 2005). Reduction action of the Msr system may prevent irreversible protein 
damage, contribute to cellular antioxidant resistance, and regulate protein function. Evidence for 
a role of the Msr system in antioxidant defense is demonstrated by the adverse effects resulting 
from MsrA ablation (Moskovitz et al. 1995, 1997, 2001). Furthermore, over-expression of MsrA 
in various organisms and cells protects them from oxidative stress toxicity (Moskovitz et al. 
1998; Ruan et al. 2002; Romero et al. 2004). The MsrA null mouse (MsrA−/−) is hypersensitive 
to oxidative stress, accumulates higher levels of carbonylated protein and expresses brain 
pathologies associated with neurodegenerative diseases (Moskovitz et al. 2001; Pal et al. 2007); 
this evidence suggests a major biological role of the Msr system. Furthermore, the Msr enzymes 
have been shown to switch several proteins between non-active and active forms by reducing 
specific MetO residues to methionine (Oien and Moskovitz 2008). 
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The MsrA−/− mouse exhibits age-dependent lower locomotor activity and abnormal gait indices 
(Oien et al. 2008) relative to control mice. Lower dopamine (DA) levels are associated with 
altered motor performance (Carlsson et al. 2007). Surprisingly, our recent observations showed 
that MsrA−/− brains in adult mice contained significantly higher levels of DA (Oien et al. 2008). 
Moreover, pre-synaptic neuronal DA in MsrA−/− striatal slices is released at higher DA pulses 
than wild-type (WT) slices as measured by fast scan cyclic voltammetry. These results raise the 
possibility that DA function is impaired in MsrA−/− mice. Moreover, MsrA−/− mice were less 
responsive to amphetamine treatment as assayed by locomotor activity and stereotypy, 
suggesting alteration of DA signaling. Dysfunctions of the corpus striatum and dopaminergic 
signaling are linked to a range of disorders including Parkinson‟s disease (Hornykiewicz 1962), 
Huntington‟s disease (Hickey et al. 2002), schizophrenia, and obsessive-compulsive disorder 
(Saxena et al. 1998). 
The observed MsrA−/− locomotor deficits and DA abnormalities prompted us to further 
examine DA signaling events that are associated with striatal movement pathways. The 
dopamine D1 receptor (D1DR) and dopamine D2 receptor (D2DR) are closely associated with 
movement regulation, and theoretically are the DA receptors most related to the MsrA−/− 
locomotor phenotypes (Oien et al. 2008). In addition, D2DR is also expressed in its short form 
(D2DRS) that serves as an autoreceptor for dopaminergic neurons. Thus, methionine oxidation in 
either the long form of D2DR or D2DRS or a combination of both may be related to the elevation 
in DA levels observed in MsrA−/− brains (Oien et al. 2008). In the current study we investigate 
the ligand-binding capabilities of DA receptors and their coupling efficiency to G-proteins in 
MsrA−/− versus WT mice. The presented data support the hypothesis that MetO modification to 
D2DRs participates in the MsrA−/− behavioral and biochemical phenotypes. 
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Materials 
The radioligands [
3
H]SCH23390 (85 Ci/mmol), [
3
H]raclopride (84 Ci/mmol), 
[
3
H]quinpirole (50 Ci/mmol), were purchased from Perkin Elmer (Waltham, MA, USA). Non-
radioactive sulpiride, quinpirole, SKF82958, and GTPγS were purchased from Sigma, St Louis, 
MO, USA. Mouse and goat antibodies against D2DR were purchased from Abcam (Cambridge, 
MA, USA). Mouse β-actin antibodies were purchased from Molecular Probes, Eugene, OR, 
USA. 
Mice 
Mice used in these studies were WT (C57BL6/129 Sv) and MsrA−/− on the same genetic 
background at an age of 6–8 months unless otherwise noted. Both types of mice were littermates 
born to MsrA+/− heterozygous parents (Moskovitz et al. 2001). All procedures using mice were 
performed within guidelines of the NIH and KU Institutional Animal Care and Use Committee. 
Immunohistochemistry analysis 
Coronal brain sections from 12-month-old WT and MsrA−/− mice were processed as 20 μm-
thick brain sections. Sections were treated with 3% H2O2 in methanol for 30 min. After blocking 
with 1% bovine serum albumin and 3% horse serum in phosphate-buffered saline, the sections 
were incubated for 24 h with primary goat antibodies against D2DR (1 : 500 dilution, stock 
concentration of 1.5 mg/mL). Sections were then incubated with biotinylated mouse anti-goat 
IgG antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), avidin–horseradish peroxide 
solution, 0.015% diaminobenzidine, 0.001% H2O2, and finally counter-stained with hematoxylin. 
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The brain slides were washed, dehydrated, mounted, and visualized using a brightfield 
microscope with a 100× objective lens. 
Immunoblot analysis 
Equal amounts of striatal membranal protein extracts or cytosolic brain proteins (extracted as 
described below for receptors fraction) were subjected to sodium dodecyl sulfate-gel 
electrophoresis. Immunoblot analyses with anti-goat D2DR antibodies (1 : 1000 dilution, stock 
concentration of 1.5 mg/mL) were performed according to common procedures. β-actin (loading 
control) was detected by primary anti-β-actin mouse antibodies. 
Antagonists and agonists binding of D1DR and D2DR ligands 
Saturation curves of receptor binding were determined by using the common membrane 
filtration assay (Bylund and Toews 1993). Briefly, brains (striatal region of each mouse type) 
were dissected and glass-Teflon homogenized in phosphate-buffered saline with protease 
inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA). Following 
centrifugal precipitation at 20 000 g for 20 min, the supernatant was removed and saved 
(cytosolic fraction in immunoblots), and the membranal pellet was washed and precipitated again 
by centrifugation. Final pellet was homogenized in 1.0 mL of 50 mM Tris pH 7.4. Membranal 
protein fractions of 100 μg were used per assay, determined by BCA Protein Assay Kit (Thermo 
Scientific, Waltham, MA, USA). Total ligand binding was determined following incubation of 
membranal fractions with incrementing concentrations of radioligand for 2 h at 25°C. Non-
specific ligand binding was determined using the same conditions with the addition of non-
radioactive ligands, 1 mM DA for D1DR and 1 μM sulpiride for D2DR. Bound radioligand was 
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separated using a Brandel harvester (Brandel, Gaithersburg, MD, USA). Radioligand bound to 
the filter was measured by liquid scintillation counting. Specific ligand binding values were 
calculated by subtracting non-specific ligand binding from total ligand binding. The ligands used 
in the tests were: [
3
H]SCH23390 and [
3
H]raclopride as D1DR and D2DR antagonists, 
respectively, and [
3
H]quinpirole as a D2DR agonist. The range for radioactive materials used 
was between 0.03 nM and 4.0 nM (increments by serial dilution). 
GTPγS-induced inhibition of radiolabeled quinpirole binding to D2DR 
 
The ability of agonists to stimulate the dissociation of GDP and association of GTP from G-
protein was assessed using GTPγS, a non-hydrolyzable analogue of GTP (Zhang et al. 2001). 
When the agonist binds to the receptor, GDP is released from the G-protein and GTPγS binds 
(Harrison and Traynor 2003). The G-protein uncoupling on [
3
H]quinpirole binding to the D2DR 
was investigated by measuring the inhibition of [
3
H]quinpirole binding at incrementing GTPγS 
concentrations. The membrane portion of homogenized striatal regions were isolated and lysed 
in 5 mM Tris buffer by glass-Teflon homogenation. Membranal extracts (30 mg/mL; 80 μg per 
assay) were incubated with [
3
H]quinpirole (1 nM) and GTPγS (0.1, 1, 10, 100, and 1000 nM) in 
50 mM Tris buffer for 2 h at 25°C in a total volume of 1 mL. To determine non-specific binding, 
identical assays were performed in the presence of sulpiride (1 μM; racemic mixture). Unbound 
ligand was removed by Brandel filtration and the remaining bound ligand was quantified by 
liquid scintillation counting. 
The effect of MsrA enzyme on quinpirole and raclopride binding was tested by using 
recombinant yeast MsrA (10 μg) (Moskovitz et al. 1997) with 15 mM dithiothreitol (DTT; this 
alone did not affect binding). D1DR binding to the agonist SKF82958 was determined using the 
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same conditions above, except for the addition of 2 nM [
3
H]SCH23390 to quantify the 
competitive binding of non-radiolabeled SKF82958 ligand (performed because of limited 
sources of commercially available radiolabeled D1DR agonists). 
Stimulated release of DA in striatal brain sections in the presence of quinpirole and 
sulpiride measured by fast scan cyclic voltammetry 
Brain sections were prepared as previously described (Johnson et al. 2006). Mice were 
anesthetized by isoflurane inhalation. The brain was immediately removed and placed in ice cold 
artificial CSF. Artificial CSF consisted of 126 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 
2.4 mM CaCl2, 1.2 mM MgCl2, 25 mM NaHCO3, 20 mM HEPES, and 11 mM d-Glucose at pH 
7.4 and was continuously saturated with 95% O2/5% CO2 throughout the experiment. Coronal 
sections of 300 μm in thickness were made using a vibratome slicer (Leica Microsystems, 
Bannockburn, IL, USA). A single section was placed in the superfusion chamber with artificial 
CSF flowing at 34°C and a continuous rate of 2 mL/min. Each brain section was equilibrated for 
60 min prior to obtaining measurements. Quinpirole and sulpiride in artificial CSF were 
maintained in a separate reservoir and introduced through a three-way valve. 
Carbon-fiber microelectrodes were fabricated as previously described (Kraft et al. 2009). 
A single carbon-fiber with a 7 μm diameter (Goodfellow Cambridge Ltd., Oakdale, PA, USA) 
was aspirated through a glass capillary tube (1.2 mm outer diameter, 0.68 mm inner diameter, 4 
inches long, A-M Systems, Inc., Sequim, WA, USA) and pulled using a heated coil puller 
(Narishige International USA, Inc., East Meadow, NY, USA). Electrodes were trimmed to 20 μm 
from the glass seal, further insulated with epoxy resin (EPON resin 815C, EPIKURE 3234 
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curing agent, Miller-Stephenson, Morton Grove, IL, USA), and then cured at 100°C for 1 h. 
Prior to experimentation, electrodes were backfilled with 0.5 M potassium acetate. 
A triangular waveform starting at −0.4 V, increasing to +1.0 V, and scanning back to 
−0.4 V was applied at the carbon-fiber working electrode. A scan rate of 300 V/s was used with 
an update rate of 10 Hz. A head-stage amplifier (UNC Chemistry Department Electronics 
Design) was interfaced with a computer via breakout box and custom software provided by R.M. 
Wightman and M.L.A.V. Heien. A choridated silver wire was used as an Ag/AgCl reference 
electrode. The carbon fiber was inserted 100 μm into the dorsolateral caudate-putamen region of 
the striatum. The fiber was between the prongs of a bipolar stimulation electrode (Plastics One, 
Roanoke, VA, USA), which were separated by 200 μm. Current was measured at 0.6 V, which is 
the oxidation potential for DA. DA release was measured in the presence of either 1 μM 
quinpirole or 5 μM sulpiride as previously described (Fawaz et al. 2009) using a 30-pulse 
stimulus train at a stimulation frequency of 60 Hz. During stimulation and DA release, stabilized 
scans of 15 s were collected every 2 min and averaged as 4-min time blocks. 
Locomotor activity measured by force-plate actometer 
The force-plate actometer and methods of data analysis have been previously described 
(Fowler et al. 2001). Briefly, the force-plate actometer consists of a low mass and highly stiff 
5 mm thick plate (28 cm × 28 cm). This plate is supported by four Sensotec Model 31 load cells 
(0–250 g range). Each force plate is positioned below a Plexiglas cage that confines the mouse to 
the force-sensing plate and is encased in sound-attenuating cubicle. Horizontal movements of the 
mouse were recorded along the sensing surface with a spatial resolution of 1 mm and a temporal 
resolution of 0.01 s. 
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The duration of recording sessions was based upon preliminary experiments and relevant 
literature assessing spontaneous locomotor activity (Geter-Douglass et al. 1997; Usiello et al. 
2000; Wang et al. 2000). The effects of the drugs used on locomotor activity were apparent 
within the initial period of 45 min following drug injection. Thus, 45-min periods were 
determined to be sufficient to monitor the locomotor response to the performed treatments. Total 
distance traveled per animal was measured and analyzed by 2-way anova (two mouse types) with 
repeated measures on the time block and session factors. 
Administration of agonists of D1DR and D2DR for locomotor activity analyses 
Prior to treating the mice with D1DR or D2DR agonists, the WT and MsrA−/− mice 
received intraperitoneal injection with 0.9% saline as a vehicle control and spontaneous 
locomotor activity was monitored for 45 min using force-plate actometers. After 4 days, the 
same mice were injected with either quinpirole (D2DR agonist, 0.1 and 0.5 mg/kg) or SKF82958 
(D1DR agonist, 0.3 and 1.0 mg/kg) and locomotor activity was monitored for 45 min. A 
minimum of 4 days between trials was used to minimize potential carryover effects. Different 
sets of animals were used for each drug to prevent cross-reactivity and carryover effects between 
drugs. The drugs were administered at volume of 5 mL/kg. 
MetO residues in recombinant long form of D2DR third intracellular loop 
The long form of rat D2DR third intracellular loop (D2DRL-IC3) was expressed as a 
glutathione S-transferase (GST) fusion protein in bacteria (gift from Dr. Kim Neve, Oregon 
Health & Science University) and purified according to published procedures (Lan et al. 2009). 
The protein was oxidized overnight with 200 mM H2O2 and excess oxidants were removed by 
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catalase. In parallel, oxidized protein was reduced with recombinant poly-His-tagged yeast MsrA 
(10 μg) (Moskovitz et al. 1997) in the presence of 20 mM DTT for 1 h at 37°C (DTT alone does 
not reduce MetO residues under these conditions). After reduction, all proteins (non-treated, 
H2O2-treated, and MsrA-reduced) were subjected to gel-electrophoresis followed by Commassie 
blue staining for the isolation of the corresponding GST-D2DRL-IC3. Bands corresponding to the 
predicted weight of ∼54 kDa were excised and protein was isolated. The protein was subjected 
to tryptic digestion prior to analysis by a LCT Premier electrospray ionization tandem mass 
spectrometer (Waters Corp., Milford, MA, USA). The mass spectrometry analyses of the 
peptides and their MetO content were performed according to previously published methods 
(Zhang et al. 2010). 
Results 
Expression levels and ligand binding capabilities of D2DR in MsrA−/− striatum 
Postmortem brain sections from MsrA−/− and WT mice were immunostained with anti-
D2DR antibodies. The MsrA−/− striatal region exhibited higher reaction levels with the 
antibodies compared with this region in WT mice (Fig. 1a). D2DR expression levels were 
quantified by immunoblot analysis on brain extracts followed by densitometry analysis (Fig. 1b). 
Similar to the increase of DA in MsrA−/− brains (Oien et al. 2008), the up-regulation of the 
D2DR may be part of compensatory response for the dysfunction of the DA system in the 
MsrA−/− brain. 
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Figure 1.  Immunohistochemistry and immunoblot analyses of D2DR in MsrA−/− and WT 
striatum. (a) Immunohistochemistry of coronal brain sections using primary antibodies against 
D2DR. Slides were visualized using light microscope with a 100× objective lens. Brownish 
structures correspond to the presence of D2DR. Scale bars represent 10 μm. (b) Immunoblot 
analysis using primary antibodies against D2DR. Representative bands are shown in the small 
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window followed by densitometry analysis for the corresponding D2DR band in each extract 
(relative density in WT represents 100%; p < 0.01, t-test). The densities of D2DR were corrected 
for the relative densities of β-actin. 
The binding of the D2DR to appropriate ligands can reflect their expression levels and function 
in signaling. Binding of the D2DR antagonists are independent of G-protein coupling and more 
reflective of D2DR expression levels. Binding of the D2DR agonists are dependent on G-protein 
coupling and more reflective of D2DR function in signaling. Accordingly, the calculated Bmax 
value of D2DR antagonist [
3
H]raclopride was higher in MsrA−/− membranal fractions (250 ± 20 
fmole/mg protein) compared with the value of WT (140 ± 4 fmole/mg protein) (Fig. 2a). In 
addition, the Kd value for [
3
H]raclopride in both mouse types was similar (Kd of 0.70 ± 0.10 nM), 
suggesting no difference in the binding affinity of the bound antagonists to D2DR (it is 
noteworthy that the Kd values in these mice are different than rats, see „Discussion‟). The 
[
3
H]raclopride Bmax values also provide further supportive evidence to the observed elevated 
levels of the D2DR in MsrA−/− brain (Fig. 1). The calculated Bmax value of D2DR agonist 
[
3
H]quinpirole was lower in MsrA−/− membranal fractions (56 ± 7 fmole/mg protein) when 
compared with the value of the WT (140 ± 10 fmole/mg protein), while the Kd value for 
[
3
H]quinpirole binding was similar in both mouse types (0.40 ± 0.05 nM) (Fig. 2a). These 
observations suggest that the coupling ability of the MsrA−/− D2DR to the respective G-proteins 
is compromised, in spite of the higher number of receptors in MsrA−/− mice (Fig. 1). In addition, 
adding recombinant MsrA to the binding reaction mixture caused significant recovery of the 
MsrA−/− [
3
H]quinpirole Bmax value to the WT Bmax value (Fig. 2b). This latter result strengthens 
the hypothesis that lack of MsrA enhances MetO formation in D2DR, which affects D2DR 
function and expression. In contrast to relative D2DR agonist-to-antagonist Bmax differences 
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between the two mouse types (Fig. 2a and b), no significant differences were found for D1DR 
ligand binding to the antagonist SCH23390 or agonist SKF82958 between these mouse types 
(Fig. 2c and d). At relatively high concentrations, [
3
H]SCH23390 was bound to MsrA−/− and 
WT striatal fractions to a similar extent (Fig. 2c). Similar results were found when SKF82958 
was used (Fig. 2d). The SKF82958 ligand was not radiolabeled, thus binding efficiency was 
determined by its competitive binding in the presence of 2 nM [
3
H]SCH23390 as previously 
described (Nwaneshiudu and Unterwald 2009). The amounts of [
3
H]SCH23390 bound to the 
striatal fractions were significantly decreased (p < 0.05) by the presence of 16 nM of SKF82958. 
This supports the hypothesis that MsrA ablation primarily impacts the D2DR. 
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Figure 2.  Binding efficiency of ligands to D2DR and D1DR in MsrA−/− and WT membranes. 
Specific ligand binding was calculated from subtracting non-specific ligand binding from total 
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ligand binding as described in „Materials and Methods‟. (a) Representative [
3
H]raclopride and 
[
3
H]quinpirole specific ligand binding curves of D2DR. (b) Bmax of [
3
H]quinpirole binding 
presented as percent of WT Bmax value (represents 100% binding) in the absence (Control) and 
presence of recombinant yeast MsrA (rMsrA Added). (c) Binding of [
3
H]SCH23390 at a 
saturating concentration (Bmax value WT, under these conditions, represents 100% binding). (d) 
Relative binding of [
3
H]SCH23390 at a concentration of 2 nM (as in panel c) in the presence of 
2 nM and 16 nM SKF82958 concentrations. For all graphs, n = 3. Significance is denoted by * or 
†
 indicating p < 0.05 using t-test for difference by mouse type or by condition, respectively. 
 
The non-hydrolyzable GTPγS analog will reduce the binding of [
3
H]quinpirole to D2DR 
(quinpirole binds with lower affinity to uncoupled D2DR compared with coupled receptors). 
Consequently, competition curves were performed by inhibiting [
3
H]quinpirole binding with 
increasing concentrations of GTPγS. Accordingly, the maximal inhibition from the competition 
curve reflects the number of D2DR coupled to G-proteins, while the 50% binding inhibition 
concentration (IC50) from the curve reflects the potency of GTPγS to dissociate the D2DR and 
G-protein complex. The maximum binding of [
3
H]quinpirole to D2DR in MsrA−/− was ∼50% of 
the maximum binding of the agonist to the receptors in the WT brain (Fig. 3; WT = 50 ± 6 and 
MsrA−/− = 26 ± 3 fmole/mg protein in the presence of 1 μM [
3
H]quinpirole). The IC50 was found 
to be similar for both mouse types (10 ± 1 nM), which is in agreement with current literature 
(Zhang et al. 2001). These data suggest reduced G-protein and D2DR coupling in the MsrA−/− 
brain. Moreover, the similar IC50 in both mouse types suggests that the dissociation rates of the 
receptors from the G-proteins are similar. The reduced interaction of G-proteins with D2DR in 
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MsrA−/− brains could be a consequence of either lower G-protein expression or interference in 
the initial binding of G-proteins to the third intracellular loop of D2DR. There was no significant 
difference in expression of Gαi/o proteins between the two mouse types (Figure S1), suggesting 
that the observed limitation in MsrA−/− D2DR agonist binding is probably not because of 
reduced Gαi/o levels. Since the expression levels of these G-proteins seem to be similar in the two 
mouse types (Figure S1), data in Fig. 3 are supportive of compromised D2DR agonist binding in 
MsrA−/− brains (Fig. 2a) and also may reflect interference in binding of MsrA−/− G-proteins to 
the third intracellular loop of D2DR. 
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Figure 3.  Inhibition of D2DR agonist binding in striatal membrane extracts of MsrA−/− and WT 
mice in the presence of GTPγS. The Y axis values of the graph represent the specific binding 
percentage of [
3
H]quinpirole at GTPγS concentrations of 0.1, 1, 10, 100, and 1000 nM. The 
value at 100% specific binding represents maximum binding of WT D2DR to [
3
H]quinpirole at 
0.1 nM GTPγS. The maximum binding values were not significantly different from values 
obtained in the absence of GTPγS; data not shown, n = 3. 
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A shorter form of the D2DR, D2DRS, serves as an autoreceptor on the pre-synaptic membrane of 
dopaminergic neurons. This receptor has a third intracellular loop that is truncated by 29 amino 
acids, but still retains four of the eight methionine residues. D2DRS has been previously 
demonstrated to respond to the D2DR agonist quinpirole and D2DR antagonist sulpiride by 
decreasing and increasing the pre-synaptic release of DA, respectively (Fawaz et al. 2009). 
Using a similar experimental design as Fawaz et al., the pre-synaptic DA release in the striatal 
area from MsrA−/− and WT coronal sections was measured in the presence of quinpirole (Fig. 4a 
and b) and sulpiride (Fig. 4c and d). Pre-synaptic DA release was detected by fast scan cyclic 
voltammetry every 2 min, initially without any treatment and followed by treatment with a 
saturating dose of quinpirole. In the presence of quinpirole, MsrA−/− sections were less 
responsive than WT sections when both were compared to the respective initial stimulation and 
detection without the presence of drug. The DA release of the MsrA−/− pre-synaptic neurons was 
significantly higher than the decreased release of the WT pre-synaptic neurons (p < 0.05; two-
way repeated measures anova). Moreover, the MsrA−/− pre-synaptic neurons were also less 
responsive to sulpiride than WT. After sulpiride treatment, the changes in DA concentration 
from the initial non-treated measurement of MsrA−/− slices were significantly lower than the 
increased DA concentration changes of the WT (p < 0.05). These results suggest that the D2DRS 
signaling is disrupted in MsrA−/− mice. 
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Figure 4.  DA release in striatal sections from MsrA−/− and WT mice treated with D2DR 
agonist and antagonist. Coronal sections were stimulated using a 30 pulse-stimulus train and DA 
scans were collected by fast scan cyclic voltammetry. (a) A representative stimulated DA release 
plot generated from measurements in the presence and absence of quinpirole. WT, open squares; 
MsrA−/−, filled diamonds. (b) The DA release measured in 4-min time blocks of WT and 
MsrA−/− sections in the presence of quinpirole. The basal initial measurements without drug 
treatment (time block 0) were set to 100%. All subsequent measurements with quinpirole are 
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represented as a percentage of this value. (c) A representative stimulated DA release plot 
generated from measurements obtained in the presence and absence of sulpiride. WT, open 
squares; MsrA−/−, filled diamonds. (d) The DA release measured in 4-min time blocks of WT 
and MsrA−/− sections in the presence of sulpiride. The initial basal measurements without 
treatment (time block 0) were set to 100%. All subsequent measurements with sulpiride are 
represented as a percentage of the initial 100% values. For both experiments, n = 3 and p < 0.05 
for genotype determined by two-way repeated measures anova. The basal DA concentrations in 
the absence of drug were WT = 1.63 ± 0.44 μM and MsrA−/−
 
= 5.47 ± 0.36 μM. 
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The in vitro and brain section findings suggest functional changes in the DA system that 
should be expressed at the behavioral level. Consequently, we investigated the behavioral effects 
of D1DR and D2DR selective agonists on locomotor activity in MsrA−/− and WT mice. A 
significant difference in locomotor activity was observed between the mouse strains when 
injected with quinpirole. At a dose of 0.5 mg/kg, the MsrA−/− exhibited ∼40% more locomotor 
activity than WT, and at a dose of 0.1 mg/kg the MsrA−/− exhibited ∼35% more locomotor 
activity than WT (Fig. 5a; repeated measures anova for mouse type effect, p < 0.02). No 
significant difference in locomotor activity was observed between the two mouse types when 
injected with saline (Fig. 5), which is consistent with previous experiments (Oien et al. 2008). 
Given the higher expression level of the D2DR in MsrA−/− mice, these data suggest that the 
compromised responsiveness of the MsrA−/− D2DRs to the inhibitory effect of quinpirole may 
be because of irregularities in either DA binding or abnormal function of further downstream 
signaling events. Moreover, the lack of a significant dose effect in the quinpirole concentrations 
used is consistent with published data, illustrating by similar analyses that there was no dose 
effect in mice even at broader and higher dose ranges (Wang et al. 2000). 
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Figure 5.  Locomotor activity after D2DR and D1DR agonist administration in MsrA−/− and 
WT mice. Total distance traveled was measured for 45 min after intraperitoneal injections of 
saline (vehicle) or indicated drug. (a) Quinpirole injection at doses of 0.5 mg/kg and 0.1 mg/kg. 
WT, n = 7; MsrA−/−, n = 10. 
†
p < 0.01 for quinpirole effect and *p < 0.02 for the genotype 
effect, determined by anova. (b) SKF82958 injection at doses of 0.3 mg/kg and 1.0 mg/kg. WT, 
n = 7; MsrA−/−, n = 10. There was no significant effect of mouse type on SKF82958 effect, 
SKF82958 increased locomotor activity in the dose range used (
†
p < 0.01) and no dose-by-type 
interaction was detected; determined by anova. 
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In addition, MsrA−/− and WT mice were injected with two doses of the D1DR agonist 
SKF82958, and ensuing locomotor activity behavioral effects were assessed in 45-min sessions 
(Fig. 5b). The anova applied to these distance traveled data indicated no effect of mouse type, a 
significant effect of SKF82958 dose effect (repeated measures anova; p < 0.01), and no dose-by-
type interaction. These data show that the D1DR agonist did not differentially affect the two 
types of mice (no type effect, no interaction effect). As expected from the literature for several 
types of inbred mice, SKF82958 substantially increased locomotor activity in the dose range 
used here (Niimi et al. 2009). These data strengthen the idea that methionine oxidation in the 
D2DR third cytoplasmic loop plays an important role in the MsrA−/− phenotype (the D2DR third 
intracellular loop contains eight methionines, and the D1DR C-terminus cytoplasmic region 
contains only one methionine; both of these regions are directly involved in signal transduction). 
Oxidation vulnerability was examined with recombinant GST-D2DRL-IC3 and peroxide 
exposure. Non-H2O2 oxidized GST-D2DRL-IC3 protein, H2O2 oxidized GST-D2DRL-IC3 
protein, and H2O2 oxidized GST-D2DRL-IC3 proteins treated with MsrA were all subjected to 
mass spectrometry analysis following gel-electrophoresis separation and tryptic digestion. The 
procedure used to detect peptides by this mass spectrometry analysis (Zhang et al. 2010) 
normally causes some methionine oxidation. To compensate for this, averaged MetO levels 
detected in the non-H2O2 oxidized GST-D2DRL-IC3 peptides were subtracted from the H2O2 
oxidized forms of the protein (+/− MsrA and DTT). A 17-amino-acid peptide produced by 
collision-induced dissociation was found to contain the highest quantity of oxidized methionine 
(276-AQELEMEMLSSTSPPER-292; Fig. 6). Furthermore, the Met283 residue (present in 
daughter ion Y10) of the peptide was found to be relatively more oxidized in comparison with 
the Met281 residue (present in daughter ion Y12; data not shown). The net oxidation level of 
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Met283 treated with H2O2in vitro was on average 2% (Fig. 6). This oxidation level resembles the 
basal physiological level of MetO in unpublished observations and in yeast cells without H2O2 in 
the growth media (Moskovitz et al. 1997). Accordingly, the current in vitro condition of 
oxidation may resemble physiological methionine oxidation. The addition of MsrA and DTT to 
oxidized GST-D2DRL-IC3 protein was able to reduce the sulfoxide of Met283 by 60% (Fig. 6). 
The MsrA enzyme can reduce only the S-form of MetO. Empirically, the distribution ratio of S to 
R forms of MetO is 1 : 1 (Oien and Moskovitz 2008). Typically, we observed that in vitro 
oxidation of methionine by H2O2 results in 60%S-MetO and 40%R-MetO (determined by amino 
acid analysis separation; unpublished results). Thus, the ability of the MsrA to reduce 60% of the 
total oxidized Met283 reflects the expected maximum reduction capability of the enzyme in an 
expected MetO racemic mixture of R and S forms following methionine oxidation by H2O2. In 
addition, the preferred oxidation of Met283 suggests this residue is more vulnerable to oxidation 
and also readily accessible to the reducing function of MsrA. 
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Figure 6.  Oxidized methionine residues in D2DRL-IC3 recombinant protein. The short and long 
form D2DR differ by a 29-amino-acid region in the third cytoplasmic loop, which begins after 
amino acid 241 in the rat sequence (underlined). The methionines (m) are in bold. The 
corresponding recombinant fusion protein GST-D2DRL-IC3 was isolated and resulting peptides 
were subjected to tandem mass spectrometry after trypsin digestion. The sequence of the major 
oxidized peptide identified is shown and also indicated in the sequence by parenthesis. 
Representative relative signal levels for the daughter ions of the major peptide detected after 
collision-induced fragmentation are presented as relative intensity of each ion. The difference in 
percent methionine (Y10) oxidation between the presence and absence of rMsrA was found to be 
significant (three experiments, p < 0.05 by t-test). 
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Discussion 
This study describes for the first time the possible effects of methionine oxidation on DA 
receptor function in vivo by using MsrA−/− mice. Previously, we observed an inverse 
relationship between abnormally high levels of DA accompanied by lowered locomotor activity 
in MsrA−/− mice (Oien et al. 2008). This is paradoxical because chronically low levels of brain 
DA are associated with Parkinson‟s disease-like motor effects including low levels of locomotor 
activity. These unexpected results led us to investigate that the alteration of DA receptor function 
and expression may be involved. 
Both the D1DR and the D2DR modulate striatal information processing that is integral to 
the translation of cortical plans into actions by providing for the expression of selected motor 
responses with concurrent suppression of unwanted responses („responses‟ may be cognitive or 
motor). The D2DR are of particular clinical interest because of their role in neuropsychiatric 
disorders, such as schizophrenia, where D2DR antagonists are therapeutic (Lieberman et al. 
2008), or their role in the movement disorder, Parkinson‟s disease, where D2DR agonists are 
known to benefit patients (Pahwa et al. 2004). Thus, we predicted a reduced expression of 
striatal D2DR in MsrA−/− mice to explain the relative lower locomotor activity (Oien et al. 
2008). Surprisingly, there was an increase of D2DR expression in MsrA−/− mice (Fig. 1). Higher 
levels of [
3
H]raclopride binding to D2DR confirmed this increase (Fig. 2). The higher protein 
levels of the D2DR in MsrA−/− may be part of a compensatory mechanism for the accumulation 
of oxidized D2DR. In spite of the higher D2DR levels observed, the binding of [
3
H]quinpirole 
suggests a compromised agonist binding of the D2DR in MsrA−/− brain (Fig. 2a). Supportive in 
vivo data to this phenomenon are demonstrated by the lesser D2DR agonist inhibitory effect on 
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locomotor function in MsrA−/− mice (Fig. 5a). Agonist occupation of G-protein coupled 
receptors leads to a cellular response that wanes, or desensitizes, with prolonged agonist 
exposure. MetO in the intracellular loops of the D2DR may cause a conformational change that 
may result in uncoupling of the receptor to G-protein subunits. The relative compromised 
binding of the D2DR to [
3
H]quinpirole suggests lower efficiency in D2DR-G-protein coupling. 
Indeed, our data show that although the levels of Gαi/o are similar in both mouse types 
(Figure S1), the coupling of D2DR to G-proteins is reduced by ∼50% in MsrA−/− relative to WT 
brain (Fig. 3). This suggests that the total Gαi/o coupling capacity is reduced in MsrA−/− brain 
rather than their coupling affinity to D2DR. 
The ability of MsrA to restore D2DR agonist binding in MsrA−/− striatal extracts 
(Fig. 2b) supports the theory that methionine oxidation of D2DR occurs in the MsrA−/− brain. 
Accordingly, it may be beneficial to cause striatal over-expression of Msr to prevent MetO 
related abnormalities manifested by oxidized D2DR. Furthermore, the selectivity of the effect of 
methionine oxidation on D2DR (by MsrA ablation) was demonstrated by the similar binding of 
D1DR to striatal extracts in both mouse types (Fig. 2c and d). Data presented in Fig. 4 suggest 
the autoreceptor function of D2DR in MsrA−/− striatum is compromised in its functional 
response to quinpirole and sulpiride compared to WT D2DRS. The in vivo observation that 
MsrA−/− mice are less responsive to the inhibitory effect of quinpirole on locomotor activity 
(Fig. 5a) supports the conclusion that there is a general malfunction of MsrA−/− D2DR. 
Furthermore, the in vivo specificity of the MsrA ablation effect to D2DR is strengthened by the 
similar response of both mouse types to D1DR agonist (Fig. 5b). According to the literature, the 
use of the administrated doses of 0.1 and 0.5 mg/kg quinpirole are within the common range 
used in mice. In mice, there is no increased locomotor response as the dose is increased; instead, 
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a suppression of locomotor activity is observed (Geter-Douglass et al. 1997; Usiello et al. 2000; 
Wang et al. 2000). Mice are different from rats in their response to quinpirole. In rats there is an 
increase of locomotor response with a higher quinpirole dose (Eilam et al. 1991; Koeltzow et al. 
2003). This observation maybe is linked to observed difference in the ligand Kd values in rats 
(Levant et al. 1992) vs. mice (current study). 
Taken together, it is suggested that lack of MsrA leads to methionine oxidation in both 
long and short forms of D2DR and diminishes their overall function efficacy. The general 
lowered MsrA−/− response to quinpirole, both in vitro and in vivo (Figs 2 and 5) implies that 
conserved regions of both D2DR subtypes are primarily affected in the MsrA−/− mouse (this 
does not exclude involvement of the 29 amino acid sequence that is not present in the D2DRS). 
The compromised G-protein coupling in MsrA−/− may be a result of oxidative modification of 
specific methionine residues, especially in the cytoplasmic loops of the D2DR that are important 
for G-proteins coupling (i.e. D2DRL-IC3) (Montmayeur et al. 1993; Ilani et al. 2002). To assess 
the possibility of methionine oxidation in D2DRL-IC3 and reversal by MsrA in vitro, a 
recombinant GST-D2DRL-IC3 protein was oxidized and treated with recombinant MsrA. An 
oxidation of a specific methionine (Met283) in recombinant GST-D2DRL-IC3 protein occurred 
and was reduced to methionine by 60% with MsrA (Fig. 6). Met283 is present in both subtypes 
of D2DR and may be an important target for oxidation that affects the general function of this 
receptor. Future experiments are underway to monitor in vivo MetO levels and location in the 
D2DR of MsrA−/− mice. Overall, the collective evidence indicates that primarily D2DR related 
signaling is affected in MsrA−/− mice. However, the contributions of other signaling events to 
the observed abnormalities will still need further investigations. 
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Mechanistically, we suggest that oxidation of specific methionine residues may also 
affect phosphorylation of adjacent amino acids in D2DRL-IC3, thereby altering DA signal 
transduction pathways. For example, a regulatory role of MetO in protein phosphorylation was 
recently reported (Emes 2009; Hardin et al. 2009; Oien et al. 2009). Accordingly, it is possible 
that specific MetO residues in D2DRL-IC3 inhibit phosphorylation events that are important for 
proper coupling of the receptor to G-proteins as well (Namkung et al. 2009). 
Our data can be interpreted to suggest that lack of MsrA in mouse brain causes D2DR 
malfunction via G-protein uncoupling leading to the production of higher DA levels (as a 
potential compensatory mechanism), reduced locomotor activity, and diminished behavioral 
responsiveness to D2DR agonists (Oien et al. 2008). Understanding the role of MsrA and MetO 
in DA physiology may result in identifying other proteins and neurotransmitter receptors that are 
altered by oxidative modification of methionine. 
Recently, it was reported that mutations in the upstream region of MsrA may be potential 
markers for schizophrenia. If this proves true, research clearly supports the relevance of the 
MsrA−/− DA system to the occurrence of DA-related abnormal behavior (Walss-Bass et al. 
2009). 
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